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Methylation of histone 3 lysine 4 (H3K4me3) is an epigenetic mark for active transcription, 
which is mediated in mammals by six enzymes of the SET1/MLL family of histone 
methyltransferases (KMTs). All of them have been linked to schizophrenia, 
neurodevelopmental disorders and intellectual disabilities in humans, but the exact 
molecular functions of these enzymes in the adult brain remain unclear. In this study we 
have assessed the consequences of the conditional loss of function of one of the KMTs, the 
Setd1b histone methyltransferase, from excitatory neurons of the adult murine forebrain. 
We have evaluated the cognitive abilities of the conditional knock-out (cKO) mice through 
behavioral tests, analyzed changes in the chromatin landscape and gene expression profiles 
by neuron-specific ChIP sequencing, RNA sequencing and single cell RNA sequencing. We 
also made an attempt to restore the severe behavioral phenotype we observed for Setd1b 
cKO mice with the histone deacetylase inhibitor Vorinostat. In previous studies of our 
group, we have shown the importance of two other SET1 members for memory 
consolidation and epigenetic programming, Kmt2a and Kmt2b. However, by comparing 
all three cKO mice for the respective KMT, we found out that the loss Setd1b impacts 
neuronal identity genes most significantly and leads to a more drastic impairment of 
cognitive performance in mice. Our study suggests that Setd1b-related gene-expression 
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The onset of big data science can be regarded as a paradigm change in our approach to 
understand diseases. Being able to read the genomics, epigenetics, transcriptomics, 
proteomics and posttranslational modifications of proteomics, gives us a unique 
opportunity to understand the underlying causes of disease in their molecular details. Of 
special interest in the epigenetics field are the so-called chromatin readers, writers and 
erasers, who are maintaining the sensitive equilibrium of the epigenome globally1. The 
ability to extract high resolution information about what these chromatin modifiers are 
doing in a specific patient due to increased efficacy and reduced costs of the new 
technologies, enable us to study rare diseases in a personalized medicine approach. It 
remains a captivating thought, that some diseases might find their origin in a single 
chromatin modifier mutation. If such a gene could be identified and the protein 
dysfunction efficiently treated through pharmacological agents, such diseases could be 
treated causally.    
 
We are interested in neurological disorders, and the focus of the first part of my thesis 
lays on the Setd1b (SET Domain Containing 1B), a histone lysine methyltransferase. 
Being a global histone methyltransferase, the gene is implicated in multiple categories of 
biological functions, such as development, hematopoiesis, cancer and also neurological 
disorders2. Setd1b has been identified as one of the key affected genes in the very rare 
12q24.31 syndrome, which is defined by intellectual disability, autism, epilepsy and 
craniofacial anomalies3,4. With the 12q24.31 deletion being the smallest known 
microdeletion syndrome up to date, it is tempting to assume that the affected genes also 
play a role in many other neurological disorders. As an example, 2-3% of the general 
population are affected by intellectual disability, of which one fourth can be attributed to 
a genetic disorder5. As for the year of 2013, 95 million cases of intellectual disability do 
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not have a known cause6. It is therefore highly likely, that the genes associated with the 
12q24.31 syndrome are also affected in these unknown origin cases of intellectual disorder. 
If pharmacological treatment becomes available, diagnostic tests for such genes could enter 
the neurological clinical routine. For such neuro-drug development, basic research has to 
provide the knowledge foundation.  
 
For Setd1b loss of function mutations in neurological disorder patients, DNA methylation 
analyses have shown hypermethylation of active promoters and enhancer regions7, this 
might be due to Setd1b mediated H3K4 methylation loss at specific loci. However, it has 
not yet been shown whether Setd1b is interacting with these loci under physiological 
conditions. To answer this question, we have used a Cre-inducible Setd1b knockout mouse 
as the central model of our studies. We have assessed the cognitive abilities of the 
knockout mice through behavioral studies and the epigenetic loci affiliation of Setd1b 
through ChIP-seq and single-cell RNA-seq. Utilizing this powerful model with cutting 
edge sequencing technology, we wish to unravel the physiological functions of Setd1b on 
chromatin and behavior in vivo. 
 
1.1. Chromatin modification  
 
The chromatin structure in the eukaryotic nucleus is mainly determined by histone 
proteins. DNA is coiled around these histones, forming nucleosomes, which make up the 
basic structure of chromatin. Nucleosomes consist of histone octamers, a combination of 
each two H2A/H2B and two H3/H4 histone dimers, with 147 bp of DNA wrapped around 
them. This interaction is facilitated by the DNA negative and the histone positive charge. 
Posttranslational modifications (PTM), which are enzymatic alterations of specific histone 
residues, are able to modulate this interaction, which alters the density of chromatin 
packaging from loose euchromatin to highly condensed heterochromatin and vice versa8. 
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Relaxation of chromatin enables transcription factors (TF) to access the DNA, which can 
either lead to the activation or repression of RNA transcription. The most prominent 
PTM include histone-methylation, acetylation, phosphorylation, ubiquitination and 
SUMOylation9. Histone-methylation will be the main focus of our work. 
 
1.2. Chromatin writers: Histone methyltransferases  
 
Chromatin can be in an active, poised or silent condition, these states are mediated by 
histone PTMs10 and appear to be primarily determined by histone methylation, creating 
a central histone methylation code. Epigenetic control via histone methylation is regulated 
by the opposing actions of histone methyltransferases (KMT) and lysine demethylases 
(KDM)11. Histone methylations dominantly occur on the sidechains of lysine and arginine 
on histones H3 and H4. Unlike acetylation and phosphorylation, methylation does not 
change the histone charge but the hydrophobicity. Sequential addition of methyl-groups 
results in histone mono-, di- or trimethylation, which leads to differential histone 
conformations10. Specific histone lysine residues can be subjected to methylation, which 
then impacts transcriptional initiation, elongation and chromatin silencing. Histone 
methylation has been confirmed at H3K4, H3K9, H3K27, H3K79, H4K20 histone lysine 
sites12,13. In our study, we focus the H3K4 methylation, which is associated with global 
transcription regulation and represents an epigenetic tag of promoter and enhancer 
regions. ChIP-seq studies of the human brain have revealed H3K4me3 marks to be 
organized in over thirty thousand peaks throughout the genome, they mostly reside on 
transcription start sites (TSS) in promoter proximal regions and correlate with RNA 
polymerase II occupancy at active gene expression sites13. In our work, we have utilized 
the chromatin immunoprecipitation technique with the next-generation sequencing 
technology (ChIP-seq) for the H3K4me3 histone modification, which enables us to detect 
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and characterize H3K4me3 mediated epigenetic functions in the Setd1b deficient genome 





Figure 1-2-1: Post-translational histone modifications in activated and silenced states 
of chromatin14. The Trithorax group of proteins transfers the chromatin activating marks 
H3K4me3 and H3K27ac, leading to relaxation of the chromatin, whereas the Polycomb 
group of proteins promote the H3K27me3 chromatin repressing marks, which lead to the 
condensation of chromatin. 
 
H3K4 methylation is mediated by the KMT2 (Lysine-N-methyltransferase 2) family of 
proteins, which is called the MLL (Mixed-lineage 10 leukemia) protein family in humans. 
The functional methyl group transferring domain of these proteins is the so called SET 
(Su(var)3-9, Enhancer(zeste) and Trithorax) domain, with the exception of Dot1, which 
methylates H3K79 without a functional SET domain8. The SET1 domain is conserved 
from yeast to humans, with H3K4 methylation being an important epigenetic modification 
in eukaryotic gene expression, playing important roles in transcription and chromatin 
dynamics. Initially discovered in yeast (Saccharomyces cerevisiae), which only possess one 
H3K4 methyltransferase, it was purified as the COMPASS (Complex Of Proteins 
Associated with SET1) complex, which has seven other components15. In fruit flies 
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(Drosophila melanogaster), the gene family already diversifies into three groups, the 
trithorax (Trx), trithorax-related (Trr) and Set1 proteins. In mammals, including humans, 
six SET-related methyltransferases can be found: Trx-related Mll1 (Kmt2a) and Mll2 





Figure 1-2-2: Taxonomy and evolution of Set1 proteins17. Set proteins are conserved 
among eukaryotes from yeast to humans. Diversification among homologues occurs with 
evolution, conservation of interaction partners can be observed. Mll1=Kmt2a, 
Mll2=Kmt2b, Mll3=Kmt2c, Mll4=Kmt2d. 
 
SET1/MLL proteins alone are enzymatically inactive, therefore they are part of a larger 
complex, which consists of several sub-complexes (WRAD: WD-40 repeat protein 5 
(WDR5), Retinoblastoma binding protein 5 (RBBP5), Absent small homeotic 2-like 
(ASH2L) and Dumpy-30 (DPY-30)), for specific methyltransferase activity towards 
H3K417. WRAD proteins are part of the functional complex in all SET1/MLL transferases. 
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Further factors are Menin, Hcf1 (host cell factor 1) and Cxxc1 (CXXC-type zinc finger 
protein 1), which are only associated with a subgroup of family members. Evidence for 
the necessity of complex integrity comes from the observation that deletion of any 
mammalian complex subunit leads to a drastic reduction of H3K4 methylation18, whereas 
the deletion of single SET1/MLL methyltransferases does so only minimally, most likely 
due to their redundancy19.  
 
 
Figure 1-2-3: Protein domain structures of human histone methyltransferases: CXXC 
- finger protein 1, Bromo - bromodomains, RRM - RNA recognition motif, HMGI - high 
mobility group I, FYRN, PHD - plant homeotic domain, FYRC-FY-rich N-terminal, 
FYRC-FY-rich N-terminal16. Mll1=Kmt2a, Mll2=Kmt2b, Mll3=Kmt2c, Mll4=Kmt2d. 
 
1.3. Chromatin erasers: Histone demethylases 
 
To maintain chromatin homeostasis, histone methylation can be removed. This is achieved 
by a group of proteins called histone demethylases. Histone methylation was supposedly 
irreversible, as the half-life of histone methylation was as long as the half-life of histones 
themselves20. This perception was changed by the discovery of the first histone 
demethylating enzyme, Lysine-specific histone demethylase 1A (Lsd1) or Lysine (K)-
specific demethylase 1A (Kdm1A), a homologue of nuclear amine oxidases21. Subsequently, 
two families of histone demethylases have been characterized, a flavin adenine dinucleotide 
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(FAD)-dependent amine oxidase group, and an α-ketoglutarate-dependent hydroxylase 
group, which furthermore needs an Fe(II) metal catalyst22. The molecular mechanism in 
both families is the hydroxylation of the target methyl group, followed by the dissociation 
of a formaldehyde molecule. Histone demethylases are large proteins with various domains, 
each with a specific function, which are histone, DNA or nucleosome binding, substrate 
recognition, enzyme function and cofactor binding. Biochemical cofactors include FAD, α-
ketoglutarate and Fe(II)23. Important domains include zinc-finger domains for DNA 
binding, PHD-finger domains for substrate recognition, amino oxidase domains for the 
catalytic function and the Jumonji domain as a cofactor binding site24. 
 
A subclassification of histone demethylases can be made by distinguishing substrates 
specificity, this is done by the subdivision into the KDM1-KDM6 families. KDM1A 
recognizes mono- and di-methylated H3K4 and H3K9 residues, whereas KDM1B acts only 
on mono- and di-methylated H3K4 modifications. The members of the KDM1 family play 
crucial roles in embryogenesis, cellular differentiation and oogenesis20. Deletion of either 
KDM1A and KDM1B leads to embryonic lethality in mice25–27.  
The KDM2 family consists of KDM2A and KDM2B, in which KDM2A recognizes di-
methylated H3K36 and tri-methylated H3K4 histone modifications and KDM2B only acts 
on mono- and di-methylated H3K36. They have been associated with functions in 
oncogenesis and tumor maintenance20. The KDM3 family consist of KDM3A-KDM3C, 
which can all act on mono- and di-methylated H3K9 modified lysine. Interestingly, 
KDM3A knockdown in mice leads to male infertility and adult onset-obesity28, while the 
mutation has also been detected in two infertile human males29.  
The KDM4 family consists of the protein members KDM4A-KDM4D, they can all act on 
di- and tri-methylated H3K9, H3K36, H1K26 histone lysines, while their functions have 
been linked to tumorigenesis20. The KDM5 protein family of histone demethylases consists 
of KDM5A-KDM5D, which can all target di- and tri-methylated H3K4 methylated lysine. 
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KDM5 family demethylases have been associated with developmental functions, for 
instance, KDM5B is known to interact with PcG proteins30, which are involved in 
transcriptional repression, and KDM5C loss of function, which is situated on the X-
chromosome, has been associated with X-chromosome-linked mental retardation31. Finally, 
the KDM6 family of histone demethylases consists of KDM6A and KDM6B, which act on 
di- and tri-methylated H3K27 histone modifications. Their function has been implied in 
development, for instance, mutations of KDM6A has been associated with the Kabuki 
syndrome32,33. 
 
1.4. Histone acetyltransferases (HATs) and Histone deacetylases (HDACs) 
 
Besides methylation, lysine residues of histone tails can also be subjected to acetylation. 
So-called histone acetylation plays an activating role in transcription34. Mechanistically, 
the addition of a negatively charged acetyl group counteracts the protonated lysine residue 
and therefore reduces its interaction with negatively charged DNA. Subsequently, DNA 
binding to nucleosomes is reduced, allowing a better access for the transcriptional 
machinery. Furthermore, acetylated lysine residues function as binding targets for 
transcriptional activators, most importantly for proteins that harbor a bromodomain, 
which can bind acetylated lysine residues specifically35–38. The equilibrium of histone 
acetylation on chromatin is maintained by the balancing activities of histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), with HATs stimulating and 
HDACs inhibiting active transcription39,40. Histone acetylation is mainly associated with 
active promoters, however, also coding regions and even telomeres have been found to 
exhibit a certain degree of acetylation. The functions of acetylated histones outside of 
active promoters are yet to be elucidated41,42. 
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HATs consist of a large group of proteins, which are also referred to as Lysine (K) 
acetyltransferases (KATs). The nomenclature differentiates between type A nuclear HATs 
and type B cytoplasmatic HATs. Type B HATs consist of KAT1 and HAT4, they are 
located in the cytoplasm and modify histones before their transport and integration into 
chromatin43, whereas type A HATs are mainly localized to the nucleus. Based on their 
sequence homology, they are categorized in the GNAT (Gcn5-related N-acetyltransferases) 
family, which comprises of KAT2A and KAT2B, the MYST family, consisting of KAT5-
KAT8, and the p300/CBP family, which includes KAT3A and KAT3B44. The single HAT 
proteins exhibit different substrate specificities, for instance KAT3A and KAT3B are able 
to acetylate all H2A, H2B, H3 and H4 histone subtypes, whereas KAT6A only interacts 
with histone H3, and KAT8 only specifically acetylates H4K1645,46. This substrate 
specificity can be modulated by combining HATs with other factors in large protein 
complexes. As an example, the incorporation of KAT2A into the SAGA (Spt-Ada-Gcn5 
acetyltransferase) complex significantly changes its substrate specificity and catalytic 
activity47. Their conserved sequence homology, differential substrate specificity and 
activity in various protein complexes render the clinical development of HAT 
pharmacological inhibitors a real challenge. 
 
Similar to HATs, HDACs are also a large and heterogenous group of genes, with 11 
mammalian genome encoded proteins subdivided into the class I, IIa and IIb, and class 
IV family of HDACs. The class I of HDACs includes HDAC1-HDAC3 and HDAC8, they 
are ubiquitously expressed and situated mainly in the nucleus48. The class IIa of HDACs 
consists of HDAC4,5,7 and HDAC9, they exhibit an N-terminal extension, which serves 
as a docking site for MEF2 (myocyte enhancer factor 2) and the 14-3-3 protein, which can 
bind to the HDAC after the latter has been phosphorylated by either the CaMK 
(Calcium/Calmodulin-dependent protein Kinase) or the PKD (Protein Kinase D) 
kinases49,50. The binding of HDAC to 14-3-3 leads to protein shuttling from the nucleus to 
 17 
the cytoplasm51. The dissociation of MEF2 allows the binding of the HAT p300, which 
leads to the conversion of MEF2 function from transcriptional repression to activation52,53. 
This transactivation mechanism is able to implement extracellular cues in the regulation 
of transcription, and can be found in various tissues for different functions in development 
and disease54. However, the expression patterns of HDAC class IIa proteins are somehow 
more restricted than of the other HDAC families. HDAC5 and HDAC9 can be found to 
be highly enriched in muscle and heart55,56, while HDAC4 is abundant in the brain and in 
skeletal tissues57. The HDAC class IIb consists of HDAC6 and HDAC10, with HDAC6 
being the main cytoplasmatic deacetylase in mammalian cells58. It is also structurally 
unique, as it exhibits two domains with deacetylation function and a zinc finger at its C-
terminal end.  
 
1.5. Memory formation 
 
One of the mysteries and ongoing frontiers of biomedical studies is the exact mechanism, 
how memory formation, consolidation and storage works in the brain. We know that it is 
highly complex and that it involves protein synthesis, differential gene expression, 
synapses and neuronal structure. A central brain structure of memory functions is the 
hippocampus, which has been experimentally validated in rodents and humans59, 
furthermore, it is one of the first brain regions to be affected in dementia60. Anatomically, 
the hippocampus consists of two parts, the dentate gyrus (DG) and the cornu ammonis 




Figure 1-2-4: The anatomical hippocampal structure in the mouse61. CA – cornu 
ammonis, DG – dentate gyrus. 
 
Neurophysiologically, long-term potentiation (LTP) has been identified as a main 
mechanism in memory formation. Calcium influx into the synaptic cleft triggers long-term 
plasticity, which in turn leads to gene expression and protein synthesis to promote long-
lasting changes in neuronal structure62. New dendritic spines appear through de novo 
cytoskeletal protein biosynthesis and preexisting ones enlarge with enhanced AMPA 
receptor expression, which render the synapses more glutamatergic. In addition, 
cytoplasmatic calcium influx stimulates cAMP production, which activates the 
transcription factor CREB (cAMP-responsive element-binding protein) via the 
PKA/MAPK kinase pathways. CREB can be further activated through phosphorylation 
through other kinases such as CaMKII and RAS signaling, which activates the 






Figure 1-2-5: Molecular mechanism of LTP induction and gene transcription via 
CREB- activating pathways63. Extracellular signals are transduced via mitogen activated 
protein kinase (MAPK) signaling cascades, cAMP signaling and ion channel mediated 
calcium influx to activate CREB mediated transcription of plasticity associated genes.  
 
1.6. Transcription and gene expression in the brain 
 
The epigenetic modification of H3K4me3 can render chromatin more accessible for 
transcription factors and RNAPII (RNA polymerase II), which is the main RNA 
polymerase of eukaryotic RNA transcription . Prior to RNAPII association with promoter 
regions downstream of transcription start sites (TSS), the chromatin is loosened up by 
transcription factors, which act as nucleosome remodelers65. Nucleosomes make space for 
the unphosphorylated RNAPII to recognize the promoter sequence, which then initiates 
transcription. RNAPII is subsequently phosphorylated at its carboxy terminal domain on 
Ser5, whereas Ser2 is only phosphorylated when the transcription reaches the gene body 
with elongation factor recruitment66. The basal transcription factor TFIID can recognize 
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H3K4me3 through its subunit TAFIII, which carries a conserved plant homeodomain 
(PHD) finger67. TFIID acts in the RNAPII complex, indicating active chromatin reading 
for histone methylation during transcription68. In the brain, rapid transcription of 
immediate-early genes (IEG), such as c-Fos, Egr1, Arc, plays a central role in memory 
formation. They have been shown to be plasticity evoked, stimuli induced and instantly 
upregulated upon neuronal activation or behavioral tasks. Rapid IEG has been shown to 
occur in the hippocampus during hippocampal specific learning tasks, such as the Morris 
Water Maze (MWM), novel environment exposure and contextual fear conditioning, but 
also exists in other brain regions69.   
 
1.7. Histone methyltransferases in development and neurogenesis 
 
Histone methyltransferases have been shown to play a crucial role in embryogenesis and 
cell differentiation in different species70,71. They play a crucial role in the maintenance of 
stem cells, which is regulated by keeping chromatin transcriptionally permissive. Activity 
of bivalent promotors of developmental genes are balanced through Polycomb-group 
proteins (PcG), which transfer H3K27 repressing marks, and Trithorax-group proteins 
(TrxG), which deposit H3K4me3 activating marks on nucleosomes. The histone 
methyltransferase complex subunit Wdr5 is able to interact with the pluripotency 
transcription factor Oct4 and associated pluripotency maintenance factors Sox2 and 
Nanog through TrxG, which promotes the transcription of key self-renewing genes72. As 
an example, the promoters of Oct3 or Nanog in undifferentiated embryonic stem cells are 
enriched with H3K4me3 epigenetic modifications, while the majority of genes responsible 
for cell differentiation are not active or poorly expressed73,74. Furthermore, neurogenesis in 
the adult hippocampus has been shown to be under the control of epigenetic 
modifications75.   
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1.8. Neurophysiological significance of lysine methylation and associated 
pathologies 
 
Global and gene-specific elevation of H3K4me3 can be observed after contextual fear 
conditioning experiments in the murine hippocampus76. Conditional knockout mice for the 
Mll1 and Mll2 methyltransferases exhibit impairments in hippocampus-related learning 
and memory functions77,78. Furthermore, the loss of the H3K9 dimethylating enzyme 
G9a/G9a-like protein hinders memory formation in the hippocampus and impairs mouse 
normal cognitive development79. Pharmacological modulation of histone readers and 
writers are able to influence memory formation by hampering epigenetic regulation, which 
has been shown for histone deacetylase (HDAC) inhibitors80 and the Bromodomain and 
Extra-Terminal motif (BET) inhibitor JQ181. Also, the pharmacological disruption of 
lysine methylation leads to the impairment of hippocampal memory formation82. Taken 
together, memory formation in the hippocampus strongly depends on different epigenetic 
modifying proteins. 
 
Dysregulated histone methylation patterns have been associated with a growing number 
of psychiatric and neurodevelopmental disorders13,83.  To date mutations in all six human 
SET1 family members have been associated with neurodevelopmental disorders and 
syndromes.  Kmt2a was identified as a causative gene for Wiedemann-Steiner syndrome 
characterized by intellectual disability, microcephaly, hypertrichosis and short stature84. 
The protein itself contains both transcriptional activator activity, linked to C-terminal, 
and repressor activity at N-terminal, enabling the balance of both activities85. Monoallelic 
variants in Kmt2b are associated with Kmt2b-related childhood-onset dystonia. Disease 
is associated with patterned, tremulous and repetitive movements and postures. 
Sometimes patients have additional clinical manifestations, such as facial dysmorphia, 
microcephaly and seizures86. De novo variants in Kmt2c (facilitating H3K4me1 and 
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H3K4me3) are associated with Kleefstra syndrome 2 and is characterized by intellectual 
disabilities (ID), autism spectrum disorders (ASD), aggressive/hyperactive behaviors and 
craniofacial dysmorphisms87. This syndrome is also associated with haploinsufficiency of 
euchromatic histone methyltransferase 1 (Ehmt1) (facilitating transcriptional repression 
via H3K9me1 and H3K9me2 marks)88.  Kmt2d H3K4 trimethylating enzyme heterozygous 
loss-of-function is associated with Kabuki syndrome together with mutations in the 
complementary function enzyme, lysine-specific demethylase 6A (Kdm6a) responsible for 
removing H3K27me3 mark for closed chromatin89. Disease is accompanied by striking 
facial features, mild to moderate intellectual disability and postnatal growth deficiency90. 
Loss of function variants in Setd1a were identified as a risk factor for schizophrenia91 
including genome-wide association studies (GWAS)92. Schizophrenia is a severe 
neuropsychiatric disorder with the positive core symptoms (delusions and hallucinations 
associated with the loss of contact with a reality) and negative symptoms (social 
avoidance, lack of motivation and reduced speech)93.  The role of Setd1b will be described 
in the coming section.   
 
1.9. Histone acetylation in learning and memory 
 
Histone acetylation of the CA1 hippocampal region was the first histone modification 
found to be important for memory formation94,95. Subsequently, also histone 
phosphorylation96, DNA methylation97,98 and histone methylation76,77. The main mechanism 
of histone acetylation in memory formation seems to be the process of memory 
consolidation99. The activating effects of histone acetylation on transcription, specifically 
on learning and memory associated genes, such as those for synaptic plasticity, have been 
proposed to play a mechanistic role in memory formation100.  
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The pivotal role of histone acetylation in learning and memory has been shown for 
numerous diseases, including the Rubinstein-Taybi-Syndrome (RSTS), which is a rare 
genetic disease exhibiting skeletal abnormalities and intellectual disabilities with low levels 
of intelligence, associated with the loss of function of the HATs CBP or p300101. 
Specifically, impaired histone acetylation of H2A and H2B have been correlated with the 
syndrome102. CBP knockout mice resemble the human disease103, and interestingly, these 
mice are proficient in short term memory learning tasks, but exhibit specific deficits in 
long term memory experiments, suggesting a role of histone acetylation in long term 
memory consolidation104. CBP loss of function has also been described for the Huntington 
disease (HD), an autosomal dominant genetic disease correlated with chorea, cognitive 
disorders and motor impairments105, the pathophysiology is based on the expansion of an 
N-terminal polyglutamine stretch of the Huntingtin protein (Htt). In the HD, CBP is 
inactivated by different mechanisms, one being the sequestration into mutated Htt 
aggregates106, direct inhibition by soluble huntingtin protein or proteasomal degradation107. 
As a result, a decrease in histone acetylation of H3 and H4 can be observed in cells 
expressing the mutant Htt106. The lack of soluble CBP protein leads to impaired 
transcriptional regulation of neuronal genes, which in turn results neuron dysfunction. 
Another important disease correlated with altered histone acetylation is the Alzheimer’s 
disease (AD). AD etiology is multifactorial, factors contributing to its onset are aging, 
levels of Apolipoprotein E (ApoE) and the environment. For characterization, the toxic 
protein aggregates of beta amyloid and tau can be found in patient brains108. In AD, the 
balance of site directed actions between HATs and HDACs seems to be perturbed, 
chromatin regions of synaptic-plasticity related genes are hypo-acetylated, whereas genes 
involved in the generation of beta amyloids are hyper-acetylated109.   
 
The convincing evidence of altered histone acetylation in neuronal disease has prompted 
a strong interest in the development of pharmacological inhibitors against histone 
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acetylation modifying enzymes. A number of HDAC inhibitors have been designed to 
increase histone acetylation upon treatment, which do not exhibit a strong specificity for 
single HDAC isoforms124. Still, a clear clinical benefit can be seen. In the mouse model of 
RSTS, CBP heterozygous mice treated with Suberoylanilide hydroxamic acid (SAHA), 
also known as Vorinostat111,112, a small molecule HDAC inhibitor that crosses the blood-
brain-barrier, greatly improve their performance in cognition behavioral experiments102. It 
has also been shown, that administration of HDAC inhibitors can reduce the toxicity of 
polyglutamines as in the HD113,114,115,116,117. And finally, also for the AD a neuroprotective 
function of HDAC inhibitors has been shown in AD experimental mouse models118,119.  
 
1.10. Setd1b protein function in physiology and disease 
 
In our study, we have investigated the functions of Setd1b in the mouse brain. Together 
with Setd1a, they are the smallest proteins of the KMT2 family. Their structure contains 
an N-terminal RNA recognition motif (RRM) and C-terminal N-SET plus SET/postSET 
domains. The Wdr82 protein only complexes with Setd1a and Setd1b proteins and is 
required for the interaction with RNAPII (RNA-polymerase II) via the RRM domain. 
Knockdown of Wdr82 leads to a decrease of H3K4me3 levels in human cell lines120.  
 
Being able to induce global changes in the epigenome, the Setd1b methyltransferase has 
distinct functions in physiology and disease. In normal physiology, Setd1b functions have 
been implicated in development, fertility and hematopoiesis. Consequently, diseases 
associated with Setd1b dysfunction include hematologic malignancies and cancer, but also 
and most interestingly, neurological disorders2. The multitude of Setd1b functions for the 
organism has certain implications for the establishment of a Setd1b mouse model: Setd1b 
knockout mice have been reported to die after gastrulation between E10.5 and E11.5121, 
and also conditional knockout adult mice die after 30 weeks2. To study the function of 
Setd1b in the brain thus prompted the need for the establishment of a brain specific 
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conditional knockout mouse. To accomplish this goal, we have used a previously published 
transgenic mouse122 in which Setd1b was brought under the control of the Cre recombinase. 
We have then crossed this strain with another mouse line in which the Cre is induced by 
the forebrain specific CaMKII promoter123. This ensured the birth of viable Setd1b 
homozygous forebrain knockout mice, which could be used for our behavioral experiments.  
 
Setd1b has been reported to play a role in neurological disorders. Clinical representation 
of Setd1b loss of function are intellectual disability, autism, epilepsy, and craniofacial 
anomalies. Human genetic analysis of this rare condition reveal different mutational 
constellations, for one the 12q24.31 microdeletion, which involves a total of six genes, with 
the most important ones being Setd1b and the histone demethylase Kdm2b3,4,7. Further 
reported mutations are missense variants either in the SET124 or RRM125 domain, and a 
SET domain frameshift mutation126.  As previously mentioned, Setd1b loss of function has 
been associated with DNA hypermethylation7, which is an interesting observation and 
could relate to the pathological outcome of the mutation. Although a rare condition, 
Setd1b loss of function in patients could teach us a lot about the functions of chromatin 
writers in neurological diseases, as the 12q24.31 microdeletion is the smallest microdeletion 
syndrome we know up to date and the other patients seem to be single gene mutation 
cases. 
 
1.11. The impact of sugar metabolism on the Alzheimer disease 
 
In the second project, we have aimed to investigate the influence of sugar metabolism on 
the development of the Alzheimer disease (AD). As previously mentioned, AD onset is 
correlated with multiple risk factors and the regulation of epigenetic modifications is 
severely perturbed in AD patient brains109. One of the risk factors is altered insulin 
signaling, as patients suffering from diabetes type II have an increased risk to develop 
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AD127. Therefore, our hypothesis was to test whether the epigenetic signatures in the adult 
brain are dysregulated upon altered insulin signaling, which contributes to age-associated 
memory decline and AD. One of the pathways implicated in diabetes and AD is the 
insulin-like growth factor (IGFs) signaling pathway128. Most interestingly, while IGFs are 
known to be produced and act in the adult brain, there is also evidence that IGFs from 
the periphery impact on brain plasticity and memory functions129,130. One of the 
mechanisms to regulate the IGF signaling pathway is by IGF-binding proteins (IGFBPs), 
which prevent IGF action via binding and thus reducing their bioavailability131. Previous 
findings identified one member of the IGFBP family, IGFBP7, as a key factor in post-
traumatic stress disorder (PTSD)132 and as a risk factor for AD, IGFBP7 is up-regulated 
in AD mouse models, as well as in AD patient post-mortem brain tissues in an DNA-
methylation dependent manner133. Unpublished data also showed that IGFBP7 levels are 
increased in blood samples from AD patients.  
 
Insulin-like growth factor binding protein 7 (IGFBP7), also called IGFBP-related protein-
1 (IGFBP-rP1) or Mac25, belongs to the family of insulin-like growth factor binding 
proteins (IGFBPs) in mammals. IGFBPs are secreted soluble proteins regulating the 
bioavailability of Insulin, Insulin-like growth factors I and II (IGF-I, IGF-II). Mammals 
have six proteins that can bind with high affinity to the two insulin-like growth factors 
(IGFs), IGF-I and IGF-II. These proteins are called IGF binding proteins 1-6 (IGFBP1 -
6) and have diverse roles in mammals134. For instance, IGFBPs prevent IGFs from binding 
to the insulin receptor and increase the half-life of IGFs135. The seventh member, insulin-
like growth factor binding protein 7 (IGFBP7) however has a 100x lower binding affinity 
to IGF-I and IGF-II136, but its affinity an estimated 500x higher to insulin137. Still , it 
remains an important regulating factor for the availability of IGFs in body physiology138. 
In the last decades studies of IGFBP7 reveal its suppressing effect on various cancer 
diseases like breast139, prostate140, colorectal cancer141, hepatocellular carcinoma142, acute 
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myeloid leukemia143 and multiple myeloma144.  Furthermore, IGFBP7 regulates 
physiological processes independent of IGFs or insulin, by inhibiting the 
BRAF/MEK/ERK signaling cascade, it is able to induce senescence and apoptosis145. 
IGFBP7 has also been reported to play a role in the formation and homeostasis of memory 
in the brain132,146.  
 
Alzheimer’s Disease (AD) is one of the most common neurodegenerative disease 
worldwide147. AD is characterized by impairments in memory functions, personality / 
behavioral changes and a decrease of ability to execute known or learned activities. 
Initially, neuritic plaques and neurofibrillary tangles are observed in the temporal lobes of 
the brain with an eventual extension throughout the cortex148. The leading hypothesis of 
the pathogenesis of AD is the amyloid cascade hypothesis, which implies a central role for 
Aβ being responsible for oxidative injuries, synaptic / neuronal dysfunction and eventual 
neurodegeneration149. AD is caused by multiple genetic and environmental risk factors150. 
For instance, people with type 2 diabetes have a higher risk of developing AD in old age151, 
suggesting a link between insulin resistance, IGFs and IGFBPs and AD. To understand 
these connections in more detail, the mouse is a suitable model organism. For instance, 
one report has shown an increased level of IGFBP7 in the hippocampus of an AD mouse 
model133, these findings were linked to altered DNA-methylation in the promoter region of 
the IGFBP7 gene. Furthermore, an artificially increase of IGFBP7 in wildtype mice 
impaired their memory function. In another report, downregulation of IGFBP7 rescued 
impairment of Insulin Like Peptide (ILP) signaling, which takes part in neuronal activity, 
memory formation and learning152, leading to the recovery of memory function. Taken 
together, IGFBP7 is a potential biomarker and therapeutical target for AD early diagnosis 
and treatment.  
We wish to mimic the IGFBP7 situation observed in human AD patients in mouse and 
use the Cre-loxP-system to produce inducible IGFBP7 overexpressing mouse line. 
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Experimental evidence suggests an influence of peripheral IGFs on neuronal plasticity and 
memory formation in mice153,129. Therefore, mouse strain was designed to have increased 
levels of IGFBP7 in the blood by overexpressing the protein in the liver. The aim is to 
test our hypotheses, whether altered brain plasticity in response to increased peripheral 










2. Study objectives 
 
Part 1: The role of Setd1b histone methyltransferase in the mouse brain 
In the first part of this PhD project we wanted to elucidate the molecular and behavioral 
consequences of Setd1b histone methyltransferase knock-out in the murine brain. 
Interfering with methylation machinery in the mouse brain has been already reported for 
four out of six members of SET1 family of histone methyltransferases (Kmt2a, Kmt2b, 
Kmt2d and Setd1a), but not for Setd1b methyltransferase. Loss-of-function of histone 
methyltransferases is strongly associated with neurodevelopmental disorders and 
intellectual disabilities in humans but their functions and targets in the adult brain is 
poorly explored. Mechanisms underlying complex behavioral disorders can be revealed by 
studying interaction of chromatin and expression machinery. Many of mutant mouse 
strains modelling loss-of-functions exhibit behavioral abnormalities similar to human 
neurodevelopmental and psychiatric disorders. Therefore, our aims were (1) to generate 
and validate the model of Setd1b conditional knock-out from the excitatory neurons of 
the mouse forebrain, (2) to perform profound behavioral characterization of animals upon 
the enzyme loss, (3) to study transcriptome and chromatin landscape associated changes 
and identify potential target genes, (4) in case of pronounced behavioral deficits, try to 
reverse the phenotype using a pharmacological approach.  
 
Part 2: IGFBP7 overexpression as a mouse model of Alzheimer’s disease 
In the second part of my PhD project I have focused on one of the mechanisms potentially 
underlying Alzheimer’s Disease (AD), one of the most common neurodegenerative diseases 
worldwide. From the unpublished data it is known that plasma levels of IGFBP7 protein 
is increased in AD patients. Therefore, we aimed at (1) mimicking the increase of IGFBP7 
in plasma by overexpressing the protein in the liver, (2) evaluating whether this will result 
in an AD-like phenotype in mice. Taken together, we wish to unravel the impact of 
peripherally overexpressed IGFBP7 on the mouse brain on a cognitive level.  
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3. Materials and methods 
3.1. Reagents 
Complete Protease Inhibitor Cocktail    (Roche applied science,) 
DirectPCR tail-lysis buffer     (Viagen Biotech) 
DPBS        (Invitrogen) 
Dynabeads        (Invitrogen) 
GeneRuler™ 100 bp     (ThermoFischer) 
LPA         (ThermoFischer Scientific) 
Midori Green       (Nippon Genetics) 
PageRuler™ Plus prestained ladder    (ThermoFischer) 
RNAZap        (Sigma-Aldrich Co) 
SYBR Green       (Roche applied science) 
SureClean Plus       (Bioline) 
1x Histoacryl       (Braun) 
 
3.2. Technical equipment 
-80°C Freezer       (ThermoFischer Scientific) 
-20°C Freezer       (Liebherr) 
Benchmark Stereotaxic Instrument   (Myneurolab) 
Bioanalyzer High sensitivity chips   (Agilent technologies) 
Bioruptor Plus sonication device     (Diagenode SA) 
Centrifuge (5418)       (Eppendorf) 
Centrifuge 4°C (5418R)      (Eppendorf) 
Cryotome       (Leica) 
Illumina HiSeq2000      (Illumina) 
Illumina NextSeq550     (Illumina) 
FACSaria III       (BD Biosciences) 
FLUOstar Omega platereader    (BMG Labtech) 
Homogenizer IKA T19 Ultra     (Ika) 
Microcentrifuge       (Roth) 
Microsyringe pump      (World Precision Instruments) 
Multi-rotator RS-24      (Biosan) 
Nanodrop 2000       (ThermoFischer Scientific) 
Nanoliter 2000 Inkector     (World Precision Instruments) 
Odyssey Licor CLX      (Li-COR Biosciences) 
Peristaltic perfusion pump     (Heidolph) 
Pipettes ResearchPlus      (Eppendorf) 
Pipette filler S1       (ThermoFischer Scientific) 
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Refrigerator        (Liebherr) 
Roche LightCycler® 480 System     (Roche applied science) 
pH meter peqMIX plus      (Peqlab) 
Scales Practum       (Sartorius) 
Shaker Mini-Rocker      (Peqlab) 
Shaker Unimax1010      (Heidolph) 
Thermal Cycler T100TM      (Bio-Rad Laboratories) 
ThermoMixer C       (Eppendorf) 
TransBlotâ Turboä Transfer system    (Bio-Rad Laboratories) 
Vortex Genie2       (Electro Scientific Industries) 
 
3.3. Consumable materials 
DNA LoBinding tubes 1,5 ml     (Eppendorf) 
15 ml; 50 ml tubes       (Greiner bio-one) 
Glass capillaries      (World Precision Instruments) 
Microlex gloves       (Ansell) 
Disposal bags       (Roth) 
SafeSeal 1,5 ml, 2 ml microtubes     (Sarstedt) 
4-15% mini-PROTEAN® SDS-acrylamide gels   (Bio-Rad Laboratories) 
TransBlotâTurboä Midi-nitrocellulose transfer packs  (Bio-Rad Laboratories) 
Serological pipettes       (Sarstedt) 
Pipette filter tips TipOne      (StarLab) 
96-Well PCR plate, non-skirted     (StarLab) 
96-Well PCR microplate, LightCycler-type, white  (StarLab) 
 
3.4. Chemicals 
Agarose        (Roth) 
Ammonium persulphate      (Roth) 
BSA         (Roth/Serva) 
CaCl2xH2O       (Roth) 
DTT        (Roth) 
DAPI        (Vectashield) 
EDTA        (VWR) 
EGTA        (Fermentas) 
EZ prep lysis buffer      (Sigma) 
Ethanol        (Roth) 
Formaldegyde       (Sigma-Aldrich Co) 
Glycine        (Applichem) 
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HEPES        (Roth) 
KCl         (VWR) 
LiCl         (Applichem) 
Methanol        (Roth) 
MgAc2        (Applichem) 
MgCl2         (VWR) 
NaCl         (Applichem) 
Nonident P-40       (Fluka) 
Parafolmaldehyde      (Roth) 
PBS         (Roth, Invitorgen) 
PonceauS        (Roth) 
Protease inhibitor (EDTA free)    (Roche) 
Proteinase K       (Roth) 
RNaseIN plus inhibitor     (Promega) 
SDS         (Applichem) 
Sodium azide       (Applichem) 
Sodium deoxychalate     (Roth) 
Sucrose        (Applichem) 
TEMED        (Roth) 
Tris         (Applichem) 
Triton-X-100       (Roth) 
Tween20        (Roth) 
Water treated with DEPC     (Sigma-Aldrich Co) 
 
3.5. Kits and reagents 
NucleoSpin® TriPrep kit      (Macherey-Nagel) 
Pierce BCA Protein Assay Kit     (Thermo Fischer Scientific) 
Transcriptor First Strand cDNA Synthesis Kit   (Roche applied science)  
ENZO corticosterone ELISA kit    (Enzo) 
Qubit dsDNA High Sensitivity Kit    (Thermo Fischer Scientific)  
Qubit RNA High Sensitivity Kit     (Thermo Fischer Scientific)  
Zymo RNA clean & concentrator-5 kit   (Zymo Research) 
TruSeq RNA Sample Preparation v2 Kit   (Illumina) 
Takara SMART-Seq v4 Ultra Low Input RNA Kit (Takara) 
Illumina TruSeq RNA Library Prep Kit   (Illumina) 




Image Studio Lite 5.2      (Li-COR Biosciences) 
GraphPad Prism 7.0      (GraphPad) 
LightCycler® 480 Software     (Roche) 
The Integrative Genomics Viewer (IGV)   (Broad Institute) 
VideoMot2 system       (TSE Systems) 
Video Freeze®      (Med Associates) 
 
3.7. Buffers and media 
TAE buffer: 40 mM Tris-acetate, 1 mM EDTA 
TBS 10X (for 1 L): 24 g Tris-base, 88 g NaCl, pH=7.6 
TBS-T (for 1 L): 100 ml 10X TBS with 1 ml Tween 20 
Citrate buffer: 10 mM Tris-sodium citrate, 0,1% Triton-X 
SDS solution (10%): 10 g SDS in H2O 
Blocking solution: 1x TBS-T, 5% (w/v) BSA 
Running buffer 5X (for 5 L): 75.5 g Tris/HCl (pH=8.3), 360 ml Glycine, 25 g SDS 
Low Sucrose Buffer: 5mM CaCl2, 5mM MgAc2, 0,1mM EDTA, 10mM HEPES (pH=8), 
1mM DTT, 0.1% Triton X-100, PI (1:100), 320 mM sucrose 
High Sucrose Buffer: 3mM MgAc2, 0,1mM EDTA, 10mM HEPES (pH=8), 1mM DTT, PI 
(1:100), 1 M sucrose 
PBTB buffer: PBS, 1% BSA, 0.2% Tween-20, PI (1:100) 
RIPA buffer: 140 mM NaCl, 1 mM EDTA, 0.1% sodium deoxychelate, Triton X-100, 
10mM Tris pH=8, 1% SDS, PI (1:100) 
Wienmann Buffer 2X: 20mM EDTA, 100 mM Tris pH=8, 2% SDS 
IP Buffer: 140 mM NaCl, 1% NP-40, 0.5% sodium deoxychelate, 50 mM Tris pH=8, 20 
mM EDTA, 0,1% SDS, PI (1:100) 
Wash Buffer: 100 mM Tris (pH=8), 1% NP-40, 1% sodium deoxychelate, 20 mM EDTA, 
500 mM LiCl, PI (1:100) 
Nuclear storage buffer: 1x PBS (Invitrogen), 0.5% RNase free BSA, 1:200 RNaseIN plus 




3.8.  Animals 
 
3.8.1. Animal welfare 
All mice were kept in the individually ventilated cages and were exposed to 12/12 h 
light/dark cycle. Food and water were provided ad libitum. Housing and breeding was 
done at the certified animal facility in Deutsches Zentrum für Neurodegenerative 
Erkrankungen by professional animal caretakers. All animal experiments were planned 
and conducted in full compliance with the German Federal Act on the Protection of 
Animals and were approved by the responsible ministry of Lower Saxony 
(“Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit”) 
under protocol G17/2695. 
 
3.8.2. Setd1b-CamKIICre transgenic mice 
Generation of mutant mice of C57B/6J background with floxed allele for Setd1b KO has 
been described previously121. Animals with exon 5 of Setd1b gene flanked with loxP sites 
were kindly provided by the group of Franz Stewart and Andrea Kranz (Biotechnology 
center, Technische Universität Dresden). They were crossed with mice expressing cre-
recombinase under the control of the forebrain-specific Ca2+/CaMKII-dependent protein 
kinase IIα (CaMKIIα) promoter, generating conditional KO (cKO) line with selective 
ablation of Setd1b. In all experiments animals containing loxP site and not expressing cre-
recombinase were used as a control and are referred to as “WT (wild-type)” in the text.  
 
3.8.3. IGFBP7-AlbCre transgenic mice 
IGFBP7 mice containing mouse IGFBP7 allele in ROSA26 locus all over the body were 
acquired from the company “Taconic” and have C57BL/6NTac background. For the 
experiments animals were continuously crossed with AlbCre animals, expressing cre-
recombinase under liver-specific alb promoter (mice were provided by Dr. Elisabeth 
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Hessmann (Gastroenterologie, Universitats Medizin Göttingen)), which would cut out 
STOP-codon with loxP sites located in front of conditional IGFBP7 allele and leading to 
the overexpression. In the text, WTA is designated to mice containing only cre-
recombinase expressed under liver promoter, WTB to mice containing non-activated extra 
IGFBP7 allele and KI to mice with both, cre-recombinase liver expression and, therefore,  
activated extra IGFBP7 allele. 
 
3.8.4.  Genotyping 
Genomic DNA was isolated from mice tails with 200 μl of DirectPCR® Lysis Reagent 
(Viagen, USA) and 40 μg of proteinase K (Roth, Germany). Biopsies were lysed for a 
minimum of 3 hours at 55°C at 400 rpm followed by 45 min incubation at 85°C in 
Thermomixer Comfort (Eppendorf, Germany).  
PCR master mix composed is presented in the Tabl. 1. Primers were supplemented 
according to mouse line: Setd1b, IGFBP7, IGFBP7-albCre, albCre and provided in Tabl. 
2 together with expected fragment size. Cycling conditions are given in Tabl.3 and Tabl.4. 
All primers were ordered from Sigma (Germany) and diluted to 10 μM. 
Samples were run in 1,5% agarose gel with 0,06 μl/ml Midori Green dye (Takara 
CloneTech Japan) for 1 hour at 120V in 1xTAE buffer. As molecular weight standard 
ThermoFischer GeneRuler™ 100 bp was used. Fragments were visualized with FAS V 
Gel documentation System (Nippon genetics, Japan). 
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Component Amount per reaction (μl) 
Genomic DNA soluction 1  
DreamTaq Buffer 10x 2.5  
dNTP Mix (10 mM) 2  
Setd1b_F/ Igfbp7_oligo3 0.25  
Setd1b_R/ Igfbp7_oligo4 0.25  
CamK_Cre_F 0.13 μl 
CamK Cre_R 0.13  
DreamTaq polymerase 0.2 
ddH2O 18.54  
Table 1: Reaction mixes for genotyping PCRs. 
 
Name Sequence  Fragment size 
Setd1b_F gaaactcgcatgcgcttctac 696 bp Setd1b loxP allele 
507 bp WT allele Setd1b_R agttcatactgtggctgaatgg 
CamK2a_Cre_F tctcacgtactgacggtgg ~400 bp for cre+ 
CamK2a Cre_R accagcttgcatgatctcc 
Igfbp7_oligo3 tggcaggcttgagatctgg  ~500 KI allele 
Igfbp7_oligo4 cccaaggcacacaaaaaacc  
DNA_1 ggggcaatcaattgaggg 333 bp for the presence of DNA 
in the sample DNA_2 caacctctgcttggttctgg 
Table 2: Primer sequences for genotyping PCRs. 
 
Step Temperature Duration Number of cycles 
Denaturation 95°C 5 min 1 
Amplification 95°C 30 sec X35 
58°C 30 sec 
68°C 1 min 
Elongation 68 °C 7 min 1 
Cooling 4 °C ¥ 1 
Table 3: Amplification protocol for genotyping Setd1b, AlbCre lines 
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Step Temperature Duration Number of cycles 
Denaturation 95°C 5 min 1 
Amplification 95°C 30 sec X35 
60°C 30 sec 
72°C 1 min 
Elongation 72 °C 10 min 1 
Cooling 4 °C ¥ 1 
Table 4: Amplification protocol for genotyping IGFBP7, IGFBP7-albCre lines 
 
3.8.5.  Behavioral studies 
Group housed Setd1b transgenic and their wild-type littermates animals at the age 8 
weeks onwards were housed in the individual cages for at least 1 week prior to testing in 
the animal room. Mice of both genders were subjected to behavioral tests. Tracking 
experiments were performed using VideoMot2 system (TSE Systems, Bad Homburg, 
Germany). If plastic surfaces were used, they were cleaned with 70% EtOH to remove 
olfactory cues after every tested animal. Tests were performed in following order: open 
field, novel object recognition, elevated plus maze, contextual fear conditioning, nesting, 
Morris water maze, rotarod, Y-maze, social novelty test, tail suspension test, prepulse 
inhibition. 
 
3.8.5.1.  Open field  
For general locomotor ability, basal anxiety and exploratory behavior animals were 
subjected to open field test154. Animals were individually placed in a square uniform gray 
plastic arena (50 x 50 x 40 cm) and allowed to explore the area for 5 min. Virtually arena 
was divided into 16 quadrants and time spent in the 4 central quadrants was measured. 





3.8.5.2. Novel object recognition 
For the next consecutive days after the open field test, the mice were habituated with two 
identical objects for 5 min each time (training day). 24 h after, one of the objects was 
replaced by new non-identical object and mice were left to explore it for 5 min (test day). 
The relative exploration time of the novel object was measured. 
%	𝑇𝑖𝑚𝑒	𝑛𝑒𝑎𝑟	𝑛𝑜𝑣𝑒𝑙	𝑜𝑏𝑗𝑒𝑐𝑡 =
𝑇𝑖𝑚𝑒	𝑠𝑝𝑒𝑛𝑡	𝑛𝑒𝑎𝑟	𝑛𝑜𝑣𝑒𝑙	𝑜𝑏𝑗𝑒𝑐𝑡
𝑇𝑖𝑚𝑒	𝑠𝑝𝑒𝑛𝑡	𝑛𝑒𝑎𝑟	𝑏𝑜𝑡ℎ	𝑜𝑏𝑗𝑒𝑐𝑡𝑠 ∗ 100% 
 
3.8.5.3. Elevated plus maze 
Mice were placed into the center of plus-shaped maze with two open and two closed arms 
(10 x 40 cm each, walls 40 cm high) for 5 min facing the open arms. Time spent in the 
arms of both types was measured. 
 
3.8.5.4. Fear conditioning 
Associative learning and memory can be accessed with classic Pavlovian fear conditioning 
test. Experiment was controlled and recorded via NIR Video Fear Conditioning System 
(Med Associates, USA). Test was carried out in plexiglass training chamber located inside 
plastic box. Mouse was placed on a removable metal electrifiable grid floor in a sound-
proof chamber with white noise generator and 12 Watt light. On the first day (training 
day) mice were exploring the chamber for 3 min and after they received an electric foot 
shock for 2 sec (constant current, 0.5 mA) while having a white noise on the background. 
24 hours later (test day) mice were subjected to the same conditions for 3 min without 
experiencing foot-shock. The percentage freezing during training and test days were 
tracked with VideoFreeze® software provided with a system (Med Associates, USA). 
Freezing was considered if motion index was lower than threshold of 50 for at least 30 
frames per second. % Freezing was calculated by the number of measurements when mouse 




Working memory was accessed with a Y-shaped plastic runway (10 x 40 cm arms, walls 
40 cm high). Mouse was placed into the Y-maze in the triangle-shaped central platform 
and left to freely explore the maze for 5 min. % of spontaneous alterations (choice of 
“novel” arm: when animal goes into different arm then before) was scored and analyzed. 
 
3.8.5.6. Social novelty test 
Sociability and social memory were tested in the same arena as used for open field test. 
Two mice of the same age and gender as a tested mouse were placed inside metal grid 
cups, so that tested mouse could smell both of them through the grid (training day). On 
the test day, one mouse in the cup was replaced with a new one. Time spent near both 
mice was analyzed in order to evaluate the preference for a new mouse.  
%	𝑇𝑖𝑚𝑒	𝑛𝑒𝑎𝑟	𝑛𝑒𝑤	𝑚𝑜𝑢𝑠𝑒 =
𝑇𝑖𝑚𝑒	𝑠𝑝𝑒𝑛𝑡	𝑛𝑒𝑎𝑟	𝑛𝑒𝑤	𝑚𝑜𝑢𝑠𝑒
𝑇𝑖𝑚𝑒	𝑠𝑝𝑒𝑛𝑡	𝑛𝑒𝑎𝑟	𝑏𝑜𝑡ℎ	𝑚𝑖𝑐𝑒 ∗ 100% 
 
3.8.5.7. Morris water maze 
Mouse was placed into a swimming basin (1.2 m diameter) with opaque water of room 
temperature containing a submerged platform and four visual cues (star, triangle, square 
and circle, see Fig.3A). On each training day, mice were swimming for 4 times, each time 
starting from a different visual cue, for 60 sec. Escape latency of mice finding the platform 
was measured. If platform was not found during 60 sec set, mouse was guided to the 
platform gently. On the day of probe test platform was removed and mice were allowed 
to swim for 1 min. The percentage of the time spent in the target quadrant and in the 
platform area as well as number of crossings of platform area were measured. Strategy 
analysis was performed based on modified MUST-C algorithm155. Direct, corrected, focused 
and short chaining strategies represent higher cognitive performance, while circling, long 
chaining, scanning, random, thigmotaxis and passivity with moderate or poor 
hippocampal spatial memory. 
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3.8.5.8. Nest-building behavior 
Impaired nest building has been associated with autistic spectrum disorder (ASD) 
phenotype in mice155. Animals were kept in the transparent plastic cages with autoclaved 
dust-free sawdust bedding and one cotton fiber nestlet (Ancare, USA) as nesting material, 
provided 3-5 hours prior to the onset of the dark phase of the lighting cycles. Nest scores 
were accessed after two nights, since females from our experience sometimes fail to tear 
the material over one night. Scoring was done according to previously described 
methodology)156: “1” nestlet is 90% intact; “2” nestlet is partially torn (50-90% remain 
intact); “3” Shredded nestlet but nestside is not identifiable; “4” Identifiable but flat nests: 
more than 90% of the nestlet is torn; “5” A (near) perfect nest: more than 90% of the 
nestlet is torn and the nest is a crater. After nest-building test, nestlets were replaced with 
the fresh paper towels. 
 
3.8.5.9. Rotarod 
Rotarod is a behavioral test aimed at accessing motor functions, balance and coordination 
in rodents which can indicate neurological deficits157. Mice were placed on individual 
chambers of rotating drum and habituated for 4 trials when bar rotated for 180s at 5 rpm 
(training phase). If mouse was falling down, it was returned at the rod for the time 
remaining. During the test phase, mice were subjected for two trials in the same daily 
schedule with intervals 4 hours between the trials for 2 consecutive days (4 trials in total). 
During the trial that lasted 180 s rod was accelerating from 5 to 40 rpm. TSE RotaRod 
Advanced system was used for the measurements of latency to fall.  
 
3.8.5.10. Prepulse Inhibition 
Sensorimotor gating was accessed with the prepulse inhibition of startle response (PPI), 
which is very often impaired in schizophrenia mouse models158. Loudspeakers delivering 
acoustic stimuli were located above the small metal grid cage sized to restrict mouse major 
 41 
movements. Cage was standing on a sensitive transducer platform sensoring vertical 
movements of the floor. Whole system was placed inside plastic boxes with sound isolation 
(TSE Systems). On the test session, first 3 min mouse was habituated to the 65 dB 
background noise followed by 2 min baseline recording. Afterwards, mouse was exposed 
to 6 pulse-alone trials with 120 dB startle stimuli for 40 ms were applied in order to 
decrease within session habituation. For test of PPI the startle pulse was applied by itself 
or after a prepulse stimulus (70 dB, 75 dB, 80 dB, 85 dB, 90 dB intensity). An interval 
of 100 ms with background noise was applied between prepulse and pulse stimulus. The 
trials were presented in pseudorandom order with 8-22 s interval. 
The average of the maximum force (MaxG) was measured as reaction to the 120 dB startle 
stimulus and comprised startle response amplitude.  
%𝑃𝑃𝐼 = 100 −
𝑆𝑡𝑎𝑟𝑡𝑙𝑒	𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒	𝑎𝑓𝑡𝑒𝑟	𝑝𝑟𝑒𝑝𝑢𝑙𝑠𝑒
𝑆𝑡𝑎𝑟𝑡𝑙𝑒	𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒	𝑎𝑓𝑡𝑒𝑟	𝑝𝑢𝑙𝑠𝑒	𝑎𝑙𝑜𝑛𝑒 ∗ 100 
 
3.8.5.11. Tail suspension 
Depressive behavior in rodents can be measured by tail suspension test159. Mouse tail was 
manually attached with a tape to a wooden rod. Light plastic tube was placed on the tail 
to avoid climbing attempts. Mouse behavior was recorded for 5 min on a video (iPhone7, 
Apple) and time of immobility was subsequently analyzed manually from the video record 
with a stopwatch. 
 
3.8.6. SAHA oral administration 
Suberoylanilide hydroxamic acid (SAHA), also known as Vorinostat, is a small-molecule 
histone deacetylase inhibitor (HDAC) can cross blood-brain barrier and clinically 
approved for cancer therapy under the name Zolinza®. SAHA was ordered Cayman 
Chemical Co in the amount of 0.67 g was dissolved in 1 l of drinking water according to 
the publication80 together with 18 g of β-cyclodextrin (Sigma-Aldrich) that increased the 
solubility of SAHA. Vehicle group received β-cyclodextrin solution only. In order to 
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dissolve SAHA was stirred at 95°C. Dosage was calculated as equivalent of 375 mg/day 
for humans, which is within the tolerable zone. Fresh solution was provided every week 
to the animals 4 weeks prior to the onset of the behavioral testing and during the testing. 
 
3.8.7. Brain samples preparation for molecular analysis 
Animals were sacrificed by cervical dislocation. Whole brain was quickly isolated on ice. 
Dissection was undergone in 1X PBS supplemented with EDTA-free protease inhibitor 
cocktail (Roche). Regions of interest (DG, CA, cortex, cerebellum) were isolated and snap 
frozen in the liquid nitrogen. Tissue samples were stored at -80°C until processing for 
RNA and protein extraction, RNA-seq and ChIP-seq. Tissues of both genders were mixed 
for the analysis. 
 
3.8.8. Intracardial perfusion 
Setd1b mutant and control mice were dispatched using ketamine/xylazine (Ketamin 20 
μl, Xylarem 150 μl, NaCl 0,9% 30 μl, 100 μl per 10 g body weight). If animal did not 
response to toe-pinch reflex, transcardial perfusion with 4% PFA in PBS using peristaltic 
pump (Heidolph, Pumpdrive 5201) followed. Brains were extracted and incubated 
overnight at 4% PFA at 4°C, then switched to 10%, 20% and 30% sucrose solution 
subsequently till soaking.  
 
3.8.9. Immunohistochemistry 
Coronal brain sections (30 μm) were obtained with Leica cryostat at -20° C after 
embedding whole brain into Jung freezing medium (Leica, Germany) with the posterior 
plane facing down. Free-floating cryosections were washed 3 times for 5 min with PBS, 
permeabilized with 0,3% Triton X-100 in PBS for 10 min, followed by 1 h blocking in 5% 
goat serum with 0,3% Triton-X and then incubated with primary antibody overnight at 
4°C. List of antibodies used is presented in the Tabl. 5. Next day after washing with PBS, 
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sections were incubated with corresponding ThermoFischer secondary antibodies: Alexa-
488, Alexa-555 and Cy-3 in the dilution 1:1000, as well as DAPI (1:10000 in PBS), and 
mounted in Fluoromount-G (Invitrogen) mounting medium. Images were taken on Nikon 
Eclipse Ti microscope. ImageJ was used to crop images, merge channels and perform 
quantifications. 
Immunostaining of Setd1b (Bethyl) was done with prior antigen retrieval with citrate 
buffer (10 mM Tris-sodium citrate, 0,1% Triton-X in water) at 95% for 10 min with 
cryosections located on SuperFrost® Plus (Thermofischer) before washing and blocking. 
Of note, we have tested several Setd1b antibodies that were not specific to detect reduction 
of Setd1b in the cryosections of cKO mice and therefore considered to be unspecific. 
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Target protein Dilution for IHC Source Product number 
Anti-Setd1b 1:100 MBS MBS126717 
Did not work 
Anti-Setd1b 1:200 ThermoFischer PA5-66255 
Did not work 
Anti-Setd1b 1:500 Bethyl A302-281A 
Did not work 
anti-NeuN 1:100 Merck MAB377 
anti-MAP2 1:1000 Biosensis C-1382-50 
anti-Iba-1 1:500 Wako 019-19741 
anti-GFAP 1:1000 Abcam ab4674 
Table 5: Antibody list for immunohistochemistry. 
 
3.8.10. Intracranial AAV-virus injections 
Viral particles for the Cre expression under control of the hSyn promoter were obtained 
from Penn Vector Core (AAV2/1.hsynapsin.hGHitron.GFP-Cre.WPRE.SV40, University 
of Pennsylvania). For Cre-AAV, stock was diluted 1:100, what resulted in 1.76x108 genome 
copies per μl. Animals were anaesthetized with xylazine/ketamine mixture (10 μl per 1 g 
mouse weight), Analgesic (50 μl of buprex) was preadministered and an incision was made 
to expose the skull. Eyes were covered with bepanthen creme. Skull was drilled with using 
a surgical driller (Fordom). Injections were done in both hemispheres using digital 
stereotaxic manipulator (Leica Microsystems), coordinates for the injection (relative to 
bregma): anteroposterior -1.75 mm, lateral ±1 mm, dorsoventral 2 mm to target DG and 
anteroposterior -1.75 mm, lateral ±1 mm, dorsoventral 1.3 mm, to target the dorsal CA1 
region. Glass capillaries delivered the virus with a speed 350 nl/min, resulting in 900 μl of 
virus injected in each hemisphere. After surgery wound was glued with tissue glue 






3.8.11. Basal corticosterone measurement 
To measure basal corticosterone level, cKO and WT males (n/genotype=5) were 
anesthetized with CO2 and once the animals did not respond to the toe pinch anymore, 
blood was collected via cardiac puncture. Corticosterone level was measured from isolated 
plasma with ENZO ELISA kit according to manufacturer’s protocol. 
 
2.9. Molecular Biology 
2.9.1. Nucleic acids isolation 
 
DNA and RNA isolations were performed according to NucleoSpin® TriPrep kit 
(Macherey-Nagel, Düren, Germany) according to the manufacturer’s instruction. Shortly, 
brain samples were homogenized with a mortar in 350 μl of lysis buffer containing 14 μl 
of TCEP reducing agent (with a final concentration 500 mM). Then lysate was filtered 
through centrifugation for 1 min at 11,000 g, mixed with 350 μl of EtOH (70%) and 
centrifuged again for 30 s at 11,000g on the column. Flow-through was used for further 
protein extraction. After, 500 μl of DNA wash buffer were added on a column and 
centrifuged for 1 min at 11,000g, this procedure was performed twice. Afterwards flow-
through was discarded and membrane was dehydrated for 3 min. Next step 100 μl of DNA 
Elute buffer were applied onto the membrane, incubated for 1 min and centrifuged for 1 
min at 11,000g. Eluted liquid contained DNA, it was stored at +4°C. To digest residual 
DNA on a column, 95 μl of rDNase reaction mixture was applied on a membrane and 
incubated at RT for 15 min. Then membrane with RNA was washed with 200 μl of RA2 
buffer for 30 s at 11,000g and 600 μl of RA3 buffer for 30 s at 11,000g. Last wash was 
with 250 μl of RA3 buffer with 2 min centrifugation at 11,000g. RNA was eluted in 60 μl 
of RNase-free H2O at 11,000g for 1 min. The RNA concentration was measured with 
NanoDrop Spectrophotometer at the wavelength 280 nm. RNA was stored at -80°C. RNA 
extracted this was also used for whole-tissue of RNA-seq. RNA degradation was analyzed 
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at Bioanalyzer 2100 with NanoReagents RNA kit (Agilent). Only samples with RNA 
integrity number(RIN) values higher than 8.0 were used for whole tissue RNA-seq. 
 
2.9.2. Protein extraction 
700 μl of flow-through containing protein obtained with NucleoSpin® TriPrep kit was 
mixed with 700 μl of Protein Precipitator buffer, incubated at RT for 10 min and 
centrifuged for 5 min at 11,000 g. Supernatant was removed, 500 μl of 50% EtOH was 
added to the residual pellet and the mixture was centrifuged for 1 min at 11,000g. After 
removing supernatant, precipitate was dried for 10 min at RT with an open lid. Then, 
based on the size of the pellet, it was disaggregated in 20-100 μl of PSB-TCEP (Protein 
Solving Buffer) and incubated for 5 min at 95°C for complete protein dissolving and 
denaturation. After samples were cooled down, tubes were centrifuged for 1 min at 11,000g 
to pellet residual insolvable material. Recovered supernatant was utilized for protein 
quantification and western-blot. Proteins were stored at -80°C. 
 
2.9.3. Western Blotting 
Protein isolation was performed with NucleoSpin® TriPrep kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s instruction. Protein quantification was done 
with Pierce BCA Protein Assay Kit according to manufacturer’s instruction. 30 μg of 
protein were loaded on 4-15% mini-PROTEAN® SDS-acrylamide gels (Bio-Rad, USA). 
Transfer was performed with TransBlotâ Turboä Transfer system using TransBlotâ 
Turboä Midi-nitrocellulose transfer packs (Bio-Rad). Afterwards membrane was blocked 
with 5% BSA and incubated at 4°C overnight with target antibodies, see Tabl. 6. The 
next day membrane was incubated with corresponding secondary antibody (IRDye 800, 
Li-COR, 1:5000), followed by visualization and quantification of immunoblots with 
Odyssey Imager Li-COR. Values in Setd1b transgenic mice were normalized to values in 
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control littermates. Of note, we have tested several Setd1b antibodies that detected a 
band in the wild-type and Setd1b cKO mice and therefore considered to be unspecific. 
 
Target protein Dilution for WB Source Product number 
anti-Setd1b 1:200 ThermoFischer PA5-40072 
Did not work 
anti-hSET1B-C-
term 
1:100 Abcam Ab170645 
Did not work 
anti-Setd1b 1:100 MBS MBS126717 
Did not work 
anti-Setd1b  1:500 Bethyl A302-281A 
anti-β-actin 1:1000 Santa-Cruz sc-69879 
anti-H3K4me3 1:1000 Abcam ab8580 
anti-HSC70 1:1000 Abcam 19136 
anti-IGFBP7 1:1000 R&D Systems MAB2120 
Did not work 
anti-IGFBP7 1:300 ProteinTech 19961-1-AP 
Did not work 
Table 6: Antibodies used for western blot. 
 
2.9.4. cDNA synthesis 
Reverse transcription was done with Transcriptor First Strand cDNA Synthesis Roche 
Kit (Roche Applied Science, Germany). 1 μg of RNA was mixed with 2μl of random 
hexamer primers and filled up to 13 μl with PCR-grade water. The mixture was incubated 
for 10 min at 65°C in a Bio-Rad T100 Thermal cycler (Bio-Rad Laboratories, USA) and 
cooled on the ice. After, each reaction was supplemented with 4 μl of Transcriptor Reverse 
Transcriptase Reaction buffer, 0.5 μl of RNase Inhibitor, 2 μl of deoxynucleotide mix and 
0.5 μl of Transcriptor Reverse Transcriptase (total volume of the mixture was 20 μl). 
Tubes were incubated for 10 min at 25°C, 30 min at 55°C and 5 min at 85°C and then 
placed on ice. For further qRT-PCR, 15 μl of cDNA was diluted 10-times with nuclease 
free water, the rest 5 μl from all the samples were used to create the primers standard 
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curve with for serial dilutions of 1:1, 1:2, 1:4, 1:8, 1:16, 1:32 in the qRT-PCR machine. 
1:32 dilution was used as a positive calibrator. cDNA was stored at -20°C. 
2.9.5. qRT-PCR  
RNA isolation was performed with NucleoSpin® TriPrep kit (Macherey-Nagel, Düren, 
Germany) according to the manufacturer’s instruction. 1 μg of total RNA was used for 
reverse transcription with Transcriptor First Strand cDNA Synthesis Roche Kit (Roche, 
Germany). Quantitative real-time PCR (qRT-PCR) with SYBR Green PCR Master Mix 
(Roche) was performed in a Roche 480 II Light Cycler (Roche). Primers were designed 
with online tool (https://lifescience.roche.com/en_de/brands/universal-probe-
library.html). Data were normalized by Hprt housekeeping gene. For graphical 
presentation and statistical analysis, the mRNA values in Setd1b transgenic mice were 
normalized to the values in control littermates. Primers used for Setd1b deletion 
evaluation, Hprt housekeeping gene, IGFBP7 knock-in evaluation primers and expression 
of cre-recombinase and GFP are shown in the Tabl. 7. Primers used for qPCR verification 
of whole tissue RNA-seq are shown in the Supp.Tabl.17. Amplification protocol is 




Hprt Mm right  cctggttcatcatcgctaatc 









Table 7: qRT-PCR primers. 
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Step Temperature Duration Number of cycles 
Denaturation 95°C 5 min 1 
Amplification 95°C 10 sec X45 
60°C 30 sec 
72°C 10 sec 
Cooling 40 °C 30 sec 1 
Table 8: Amplification protocol for qRT-PCR. 
 








SYBR Green Mix 7.5 
UPL probe 0.15 
cDNA 3 
Table 9: Reaction mixes for qRT-PCRs with SYBR Green. 
 
2.9.6. Statistical analysis 
Statistical analysis for behavioral and molecular experiments was performed with 
GraphPad Prism software. Bars represent mean±S.E.M and significance of group 
differences was evaluated by t-test for independent samples or, when indicated, by one-
way analysis of variance (ANOVA) with repeated measures. p-values < 0.05 were 
considered significant.  
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2.10. Sequencing and bioinformatics analysis 
 
2.10.1. RNA sequencing of the whole tissue 
RNA was isolated as described in the section 2.9.1. cDNA library was prepared with 
TruSeq RNA Sample Preparation v2 Kit (Illumina) and single-end 50 bp sequencing was 
done using HiSeq2000 (Illumina). Quantity and quality of library were checked with Qubit 
dsRNA HS Assay kit and Agilent 2100 Bioanalyzer subsequently. 
2.10.2. Cell-type specific RNA isolation and RNA sequencing 
Each sample comprised of two pulled frozen CA regions from left and right hemisphere of 
two different mice. Tissues were homogenized on ice with 30 strokes plastic pestle in 1,5 
ml Eppendorf tube containing 500 μl of EZ prep lysis buffer (Sigma). This was followed 
by homogenate transfer into 2 ml tubes, adding up lysis buffer to 2 ml and incubating on 
ice for 7 min. Samples were centrifuged at 500g, supernatant discarded and the nuclear 
pellet was mixed with 2 ml of lysis buffer and incubated on ice for 7 min again. 
Centrifugation step was repeated and nuclear pellet was mixed with 500 μl of nuclei 
storage buffer and filtered with 40 µm filter (BD falcon) with extra 100 μl of nuclei storage 
buffer. Collect nuclei were incubated for 45 min with anti-NeuN-Alexa488 antibody 
(1:1000) and washed with nuclei storage buffer. Next we performed FACS sorting of the 
stained nuclei with 85 µm nozzle on FACSaria III machine. Gating was done by the size 
of the nuclei, doublets were excluded. Separation of neuronal nuclei from non-neuronal 
was based on NeuN-Alexa488 fluorescent signal. Sorted nuclei were collected into 15 ml 
falcon covered with nuclei storage buffer. RNA was extracted using Trizol LS protocol: 
After incubating nuclei with 750 μl of Trizol for 5 min, 200 μl of chloroform was added 
and incubated for 5 min. This was followed by centrifugation at 12000g at 4°C for 15 min. 
Aqueous phase with RNA was collected and processed with Zymo RNA clean & 
concentrator-5 kit with DNAse treatment according to manufacturer’s protocol. RNA 
concentration was measured with Qubit RNA HS Assay. 100 ng of RNA was used for 
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RNA-seq with Illumina TruSeq RNA Library Prep Kit and sequenced single-end 75 bp in 
Illumina Nextseq 550. Glial nuclei were prepared for sequencing with Takara SMART-Seq 
v4 Ultra Low Input RNA Kit and Illumina Nextera XT. 
 
2.10.3 List of bioinformatics tools used for RNA-seq analysis 
 
Tool Purpose Notes 
Customized 
Illumina pipeline 
Base calling  
Illumina bcl2fastq 
1.8.4 
Bcl to FASTQ conversion  
FastQC 0.11.5 FASTQ quality control  






Reads counting  
DESeq2 package of 
Bioconductor 
Differential gene expression  
EdgeR package of 
Bioconductor 
RPKM values calculation  
topGO package of 
Bioconductor 
Gene Ontology (GO) enrichment 
with weighted analysis option 
categories being 
significantly enriched with 
p<0.05 and false discovery 
rate (FDR)<0.05 
Eulerr package of 
Bioconductor 
Gene sets overlaps  
DeepTools 2.4.0 Creation of bigwig file for genome 
browser visualization 
 
Table 10: Tools used for RNA-seq analysis. 
 
2.10.4. Cell-type specific chromatin isolation and ChIP sequencing 
Neuron-specific chromatin isolation and ChIP were done as described previously with 
modifications160. Each sample comprised two pulled frozen CA regions from left and right 
hemisphere of two different mice (we utilized the remaining hemispheres from the tissues 
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used for NeuN+ RNA-seq sorting). All steps were performed on ice unless stated 
differently. Tissues were homogenized with a plastic pestle in 1.5 ml Eppendorf with 500 
μl of low sucrose buffer and fixed with 1% formaldehyde for 10 min followed by 5 min 
quenching with 125 mM glycine on rotating wheel. Suspension was centrifuged at 2000g 
for 3 min, the supernatant was discarded and the pellet resuspended in 1 ml of low sucrose 
buffer. The pellet was homogenized with a mechanical homogenizer (IKA Ultraturax T10). 
Oak Ridge centrifuge tubes were filled with high sucrose buffer and homogenized pellet 
was layered onto it, followed by centrifugation at 3148g for 10 min. Upper phase 
containing myelin was discarded and the nuclear pellet was resuspended in PBTB buffer. 
The resulting solution was stained with 1:1000 dilution Alexa Fluor 488-conjugated anti-
NeuN antibody in PBTB on a rotating wheel for 25 min, then centrifuged for 3 min at 
2000g and washed 3 times with PBTB. Stained nuclei were passed through 40 μm filters 
into FACS tubes and sorted with 85 µm nozzle on FACSaria III machine with the same 
gating parameters as described in section 2.3.2. After sorting samples were centrifuged for 
15 min at 3148g. Supernatant was discarded, and remaining solution centrifuged for 2 min 
at 10000g in DNA low binding tube. Nuclear pellet was snap-frozen in liquid nitrogen and 
stored at -80°C. For chromatin shearing the pellet was mixed with 100 μl of RIPA buffer 
and incubated on the wheel for 10 min at 4°C. Then the samples were sonicated in 
Bioruptor (Diagenode, Belgium) 30s ON/30s OFF, high power, for 25 cycles. Next, step 
samples were centrifuged at 18.000g for 5 min and the supernatant was transferred in the 
low-binding tube. Shearing check was done by decrosslinking 5 μl of sample with 20 μl of 
EB buffer and 0,1 μg/μl of RNAse A. Mixture was incubated for 30 min at 37°C, shaking 
at 450 rpm. After 1 μl of Proteinase K and 20 μl of WB(2x) buffer was added followed by 
incubation for 2h at 65°C, shaking at 1300 rpm. Samples were mixed with 3 μl of LPA 
and 46 μl of SureClean, incubated for 10 min at RT and centrifuged for 20 min at 20,000g 
at RT. Pellet was washed twice with 400 μl of 80% EtOH by centrifugation for 5 min at 
20,000g, dried for 5 min and re-suspended in 20 μl of EB. Measurement of chromatin 
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concentration was analyzed with Qubit 2.0 fluorometer (DNA HS kit) and fragmentation 
was checked with Bioanalyzer2100 (DNA HS kit). Beads preparation was done as 
following: necessary amount of protein A or IgG coated beads (Invitrogen) were washed 
once with 1 ml of IP buffer, re-suspended in 0.5 ml of IP buffer with 0.5% BSA and 
incubated for 1-2 hours at 4°C on the rotating wheel. Then beads were washed with 1 ml 
of IP buffer and re-suspended in the initially taken volume. Original samples were diluted 
10 times to reduce SDS concentration throughout the precipitation and precleared with 
20 μl of activated beads by 1h incubation at 4°C on a rotating wheel. Then tubes were 
placed on a magnetic rack, supernatant was collected, and the necessary amount of 
antibody was added and incubated overnight at 4°C on the rotating wheel. All antibodies 
used are mentioned in the Tabl. 11. Next day each sample was incubated for 1.5h with 15 
μl of the activated beads at 4°C on the rotating wheel. After placing tubes at magnetic 
rack and discarding supernatant, beads were washed twice with 1 ml of IP buffer, three 
times with 1 ml of wash buffer (last time with 5 min rotation at 4°C), and the last time 
with 1 ml of IP buffer. To isolate precipitated DNA, samples were incubated with 20 μl 
of EB with 0.1 μg/μl of RNAse A for 30 min at 37°C shaking at 450 rpm. Then 20 μl of 
WB buffer and 1 μl of Proteinase K were added to samples and mixture was incubated 
overnight at 65°C at 800 rpm. Next morning tubes were placed at magnetic rack, 
supernatant was collected, beads washed once more with 20 μl of EB and incubated for 
10 min at 65°C shaking at 800 rpm and supernatant was added to already collected one. 
After, 3 μl of LPA were added to samples and inputs, vortexed. Then 60 μl of SureClean 
were added to samples and 90 μl to inputs, vortexed and incubated for 10 min at RT, 
centrifuged for 20 min at 20000g at RT. Supernatant was removed and washed twice with 
80% EtOH. Pellet was dried for 5 min at RT and re-suspended in 30 μl of EB. ChIP DNA 
was used for library preparation using NEB Next Ultra II DNA library preparation kit 
and sequenced for single end 50bp at Illumina HiSeq 2000.  
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Anti-H3K4me3  1 µg for 0.3µg 
chromatin 
Abcam ab8580 
Anti-H3K4me1 1 µg for 0.3µg 
chromatin 
Abcam ab8895 
Anti-H3K27ac 1 µg for 0.3µg 
chromatin 
Abcam ab4729 
Anti-H3K9ac 1 µg for 0.3µg 
chromatin 
Millipore 07-352 
Table 11: Antibody list for ChIP 
 
2.10.5. List of bioinformatics tools used for ChIP-seq analysis 
 
Tool Purpose Notes 
Customized 
Illumina pipeline 
Base calling  
Illumina bcl2fastq 
1.8.4 
Bcl to FASTQ conversion 
(demultiplexing) 
 
FastQC 0.11.5 FASTQ quality control  
Bowtie2 2.0.2 Mapping FASTQ to mouse reference 
genome (mm10) 
 
SAMTOOLS 1.9.0 - PCR duplicates removal 
(rmdup -s) 
- BAM files generation 
- Merging samples of the same 
group (merge) 
 
NGSPlot 2.61.0 Profile plots from merged BAM files  
MACS2/2.1.1 
Bedtools 2.25.0 
Peak calling q value < 0.1 
Diffbind package of 
Bioconductor 
Differential binding analysis  
TopGO package of 
Bioconductor 
Pathway analysis categories being 
significantly enriched 
with p<0.05 and false 
discovery rate 
(FDR)<0.05 
HOMER 4.10 Genomic region annotation  
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DeepTools 2.4.0 Creation of bigwig files for genome 
browser visualization 
 
Table 12: Tools used for ChIP-seq analysis. 
 
2.10.6. Single-nucleus RNA-Seq 
WT mice CA tissue was used to isolate the unfixed NeuN+ nuclei same was as it was 
described in the section 2.3.2. Sorted nuclei counting was performed in Neubauer chamber 
with 10% trypan blue in PBS and resuspended to concentration of 1000 nuclei/μl. Library 
was prepared with 10X Chromium Single Cell 3' reagents(v3). According to 
manufacturer’s protocol barcoding, GEM formation, reverse transcription, cDNA 
synthesis and library preparation were performed, followed by sequencing in Illumina 
NextSeq550. 
 
Tool Purpose Notes 
CellRanger software 
(v.3.0.2) 
- Reads alignment to hg38 
genome (GRCm38.p4) 
- mapping reads to the pre-
mRNA 
Dataset of 3841 cells 
(3801 after excluding 
low quality cells) 
SCANPY package - Prefiltering 
- Normalization 
- Clustering 
DG and inhibitory 
neurons clusters were 
excluded 






Note: some of the figure legends may be identical with a corresponding paper („SETD1B 
controls cognitive function via cell type specific regulation of neuronal identity genes“, 
Michurina et al) that has been submitted for publication and is already available via 
BioRxiv preprint server (https://doi.org/10.1101/2020.08.07.240853). 
 
4.1. The Setd1b – CaMKIICre conditional knockout mouse 
 
Our lab has previously established the essential functions of Kmt2a and Kmt2b in learning 
and memory formation in the murine hippocampus77,78. We therefore hypothesized, that 
the genetic manipulation of Setd1b protein might also impact mouse cognitive functions. 
To evaluate this idea, we have used a previously published transgenic mouse model in 
which Setd1b is brought under the control of the Cre-recombinase by flanking Setd1b 
exon 5 with loxP sites121,122, and crossed it with another mouse line in which the Cre is 
induced by the forebrain specific CaMKII promoter123 (see Fig.1A). The resulting 
transgenic mouse is designed to have lost Setd1b protein in excitatory neurons of the 3 
weeks old postnatal forebrain (cKO mice). To evaluate the efficacy of region-specific Cre 
mediated Setd1b knockout, we have conducted a qPCR analysis targeting exon 5 of 
Setd1b, and indeed, we could observe a strong reduction of Setd1b in CA, DG and in the 
cortex, but not in the cerebellum (see Fig.1B). These results imply a CaMKII promotor 
region specific Cre-recombinase activity and loss of Setd1b. As the CaMKII promoter is 
specifically active in excitatory neurons, residual Setd1b expression can be explained by 
other cell types being unaffected by the knockout. Additionally, we have conducted whole 
tissue RNA-seq with CA samples, which showed a specific loss of Setd1b exon 5 in cKO 
(see Fig.1C), further confirming the functionality of the genetic mouse model. To evaluate 
the impact of Setd1b knockout on the protein level, we have conducted Western Blot 
analysis with cortical samples, and indeed we could observe a significant reduction of 
Setd1b protein in cKO hippocampal CA region brain samples (see Fig.1D).  
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Morphological assessment did not show any differences between wildtype and Setd1b 
knockout animals, neither in males, nor in females, although Setd1b cKO mice are slightly 
lighter in bodyweight (see Fig.2A). Similarly, the brains of wildtype and Setd1b cKO 
animals did not exhibit any obvious morphological differences, but Setd1B cKO brains 
were slightly lighter in weight (see Fig.2B). Immunohistochemical analysis of mouse brain 
tissue sections staining for the neuronal nuclei specific Neuronal N protein (NeuN), 
Microtubule-83 Associated Protein 2 (MAP2) as well as the microglial marker Ionized 
calcium-Binding Adapter molecule 1 (IBA1) and the astrocytic marker Glial Fibrillary 
Acidic Protein (GFAP) did not show any obvious differences between wildtype and Setd1b 
cKO animals (see Fig.2C and 2D). Interestingly, there was a trend of increased GFAP 
signal, which might be originating from astrogliosis, however, the difference was not 
significant. Taken together, the conditional knockout mouse model for Setd1b is functional 
both on mRNA and on protein level in CaMKII promoter specific brain regions, without 
inducing any gross anatomical brain aberrations. This verification enabled us to move on 
to behavioral experiments to evaluate the cognitive functions o Setd1b cKO mice in 
learning and memory formation. 
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Figure 2-1 Design and validation of the Setd1b loss-of-function mouse model. (A) Breeding scheme for 
the Setd1b cKO mouse. (B) mRNA levels of Setd1b are decreased in cortical and hippocampal (CA and 
DG) regions but not in the cerebellum (WT: n=6, cKO: n=6; * Student t-test < 0.05) (C) RNA-seq profiles 
of wildtype and Setd1b cKO mice, confirming the loss of Setd1b exon 5 in cKO mice. (D) Western Blot 
analysis of Setd1b protein levels in wildtype and Setd1b cKO mice. Setd1b protein is significantly reduced 




Figure 2-2 Setd1b cKO mice do not exhibit gross morphology changes. (A) Body weight is slightly 
decreased in cKO when compared to control animals (WT: n=15, cKO: n=15; * Student t-test < 0.05). (B) 
Brain weight  is also slightly decreased, the brain does not exhibit any obvious anatomical differences (WT: 
n=11, cKO: n=11; **** Student t-test < 0.0001). (C) Also, immunostainings of the hippocampal region do 
not reveal any histological alterations. Scale bar 100 µm. (D) Quantification of marker proteins shows no 
difference between WT and cKO brain neuronal structures. Normalized mean intensities for immunostaining 
(WT: n=6, cKO: n=6; Student t-test). Error bars indicate SEM.    
 
4.2. Setd1b Loss-of-function impairs hippocampus-dependent spatial memory 
To evaluate hippocampus-dependent spatial memory formation in Setd1b cKO mice, we 
have subjected three months old animals to the most widely used paradigm of Morris 
water maze (MWM) test161 (see Fig.3A). Test consisted of the training phase, during 
which we trained the animals to learn where the hidden platform is located based on the 
visual cues. While WT animals showed an everyday improvement in the time they were 
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managing to successfully find a platform location and reached the plateau of less than 20s 
escape latency after the 3rd day, cKO animals stopped any improvement in the latent time 
of finding hidden platform after the 5th day of training (see Fig. 3B). We also observed 
that on the very 1st day and the very first trial (when mice were for the first time 
introduced to water) groups did not show any differences in the swimming speed (data 
not shown). To exclude the effect of motor impairments, we compared the average swim 
speed for each day during learning phase. First few days speed between groups did not 
differ, however starting from the 4th day, cKO group started to differ in the swimming 
speed, resulting in approximately 10 cm/s more slowly speed than WT group on the last 
day before probe test (see Fig. 3D). To address this issue, we further performed rotarod 
test to evaluate whether Setd1b cKO exhibit motor abnormality and tail suspension 
depression test, as described in the next chapter.  After 10 days of training we have carried 
out the probe test (PT) when the platform is being removed from the setup to access 
memory retrieval. Data evaluation showed that Setd1b cKO mice performed poorly in 
remembering the site of the platform: they sent significantly less time in the area of target 
quadrant (see Fig. 3E), less time in the target itself (see Fig. 3F) and the number of the 
crossings of the area where platform used to be located is strongly reduced (see Fig. 3G).  
Next we investigated the search strategies in the maze during learning phase for the both 
groups. A modified version of the MUST-C algorithm gave the hippocampus-dependent 
readout155. We observed growing preference to select cognitively challenging strategies 
during learning among WT animal group, such as “direct”, “corrected”, “focused” and 
“short-chaining” strategies. Setd1b cKO mice had longitudinal increase “circling”, “long-
chaining”, “focused false”, “random”, “thigmotaxis” which were barely selected by WT 
group after the 3rd day of training. These strategies are considered to be less challenging 
and rather indicate poor cognitive abilities (see Fig.3C).  Taken together, we may conclude 
that Setd1b plays a role in the modulating spatial memory and its deletion from the 
excitatory neurons of the postnatal forebrain leads to significant retardation in 
 61 
hippocampus-dependent learning and memory abilities already from the 3rd month after 
birth.  Since the tested mice were of both genders, we analyzed whether females and males 
performed differently (see Supp.Fig.3) and did not discover any sex-related differences.  
We made an attempt to deliver Cre-containing adeno-associated virus to the DG region 
of WT animals (Setd1bfl/fl) in order to exclude the developmental defects upon Setd1b loss 
in our system and to evaluate purely hippocampus-dependent function. We collected DG 
region 14 days after the injection, since this timepoint has been previously shown in our 
laboratory as sufficient for viral expression. Virus expression was sufficient based on the 
amount of Cre-recombinase mRNA after injection, but we did not observe the reduction 
of Setd1b (see Supp.Fig.2A,B). To test whether Setd1b was not knocked down due to the 
increased half-life of the protein, we performed the same experiment three and four weeks 




Figure 2-3 Spatial memory is severely impaired in Setd1b cKO mice in the Morris water maze test. (A) 
Scheme of the test setup. (B) Escape latency during MWM shows poor learning performance of cKO mice 
(WT: n=15, cKO: n=15; two-way-ANOVA, genotype effect: F (1,28)=82.34; **** p-value < 0.0001). (C) 
Strategy analysis: Setd1b cKO lack cognitive challenging searching strategies. (D) Average speed during 10 
days of training (WT: n=15, cKO: n=15; two-way-ANOVA, genotype effect: F (1,14)=35,53; **** p-value 
< 0.0001. (E) % Time spent in the target quadrant during the probe test is reduced in Setd1b cKO mice 
(WT: n=15, cKO: n=15; Student t-test: **** p-value < 0.0001). (F) % of time spent in the target zone on 
the probe test day is reduced (WT: n=15, cKO: n=15; Student t-test: **** p-value < 0.0001). (G) Number 
of platform crossings on the probe test day is decreased (WT: n=15, cKO: n=15; Student t-test: **** p-
value < 0.0001). Error bars indicate SEM.   
F G 
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4.3. Setd1b knock-out affects multiple cognitive functions 
 
We assessed potential cognitive deficits of postnatal Setd1b loss-of-function in the number 
of other behavioral tests. In the open field test (OF) both cKO and WT showed the same 
levels of exploratory behavior and had no differences in the time spent in the center (see 
Fig.6A) or the speed (see Fig.6C) and distance travelled (see Fig.6B) indicating that basal 
anxiety is not affected and there is no major motor impairment.  Working memory, very 
often affected in the mouse models of schizophrenia162, was accessed with the Y-maze test, 
where we counted successful alterations as visits to arms that were not visited in the trial 
before, was not affected among cKO (see Fig.6D). Loss of Setd1b did not affect a novel 
object recognition (NOR) paradigm for hippocampal long-term memory consolidation 
(see Fig.6E). Both genotypes were spending similar time near the new object introduced 
24h after the training day. Importantly, cKO mice showed higher than 50% preference for 
the new object on the test day, showing that they could distinguish the new object from 
the old. Absence of Setd1b in the postnatal forebrain did not induce pro-depressant 
behavior as can be seen from tail suspension test (TST), paradigm used to access despair 
traits in rodents and often performed to evaluate antidepressant efficiency163. Both 
genotypes exhibited similar immobility time (see Fig. 6F), therefore it is unlikely that 
poor performance in the MWM was due to depressive phenotype and the lack of 
motivation.  In elevated plus maze (EPM), paradigm to test anxiety-like behavior, mice 
of both groups spent most of the time in the closed arms (see Fig.4B), however we observed 
that cKO spent significantly more time in the open arms (see Fig.4A). These results could 
be an indication of decreased anxiety among Setd1b cKO animals or, spoken differently, 
avoidance of the closed arms. Time in the center region did not differ among groups (data 
not shown). Total distance travelled in the arms of EPM did not differ between groups 




Figure 2-4 Loss of Setd1b affects different behaviors. (A) cKO mice spent more time in open arms of 
elevated plus maze (WT: n=15, cKO: n=15; Student t-test: *** p-value < 0.001). (B) cKO mice showed 
avoidance of closed arms maze (WT: n=15, cKO: n=15; Student t-test: *** p-value < 0.001). (C) Total 
distance travelled in EPM did not differ among two groups maze (WT: n=15, cKO: n=15; Student t-test: 
p-value=0.108). (D) Freezing of cKO mice occurred already during preliminary stage of habituation in the 
shock-chamber before electric shock during fear conditioning test (WT: n=8, cKO: n=8; Student t-test: ** 
p-value<0.01; * p<0.05). (E) Baseline startle response to 120 dB was increased in cKO mice (WT: n=8, 
cKO: n=8; Student t-test: * p-value<0.05). (F) Prepulse inhibition was not affected (WT: n=8, cKO: n=8; 
two-way-ANOVA, pulse intensity effect: F(1,14)=1.1; p-value=0.3127). Prepulse intensity still had an effect 
mice (WT: n=8, cKO: n=8; two-way-ANOVA, pulse intensity effect: F(2.2, 30.87)=21.68; **** p-value < 
0.0001). Error bars indicate SEM.  
 
We subjected animals to rotarod to test motor coordination, learning and locomotion 
impairment. Since locomotor activity has been shown to be not impaired in the open field, 
elevated plus maze and tail suspension test, results of rotarod test indicate rather absent 
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differences in the coordination and balancing, since there was no difference between two 
genotypes on the very first learning trial. However, further trials show increasing difference 
in the latency to fall off the rod between two groups (see Fig.5C), where cKO do not 
improve in the latent time. Therefore, we concluded that motor learning is mildly 
deregulated. Since we have shown that Setd1b expression levels are not altered in 
cerebellum (see Fig.1B), the phenotype we observe in this test might arise from the 
reduction of Setd1b in striatum, where CamKII is expressed164. This region has been shown 
to be involved in the motor learning on rotarod after knocking-out glutamate ionotropic 
receptor NMDA type subunit 1 (Grin1)165. Interestingly, we noticed by a casual 
observation that cKO animals failed to use paper tissues normally provided to every cage 
by the animal facility, while WT shredded provided tissues building proper nests. 
Therefore, we decided to perform nest building test based on commonly used protocol to 
assess this behavior156. WT male mice managed to shred the nestlet material and build an 
adequate nest overnight (for some WT females it took two nights), whereas only few cKO 
mice slightly shredded the provided nestlet and in the majority cages of other cKO 




Figure 2-5 Setd1b cKO mice do not build nests and have moderate motorical learning impairment. (A) 
cKO mice do not make nests as checked in nest building test (WT: n=15, cKO: n=15; Student t-test: **** 
p-value < 0.0001). (B) Photo of WT mouse in its nest and cKO on the unshredded nestlet. (C) In rotarod 
test cKO had slightly decreased motor learning (WT: n=15, cKO: n=15; two-way-ANOVA, genotype effect: 
F (1,28)=14.02; *** p-value < 0.001). Error bars indicate SEM.  
 
Since nesting is thought to be connected to social skills in mice166, we next performed 
social novelty test to see if the communication of male and female mice is affected (see 
Fig.6G). We did not observe significant difference in the time spent with novel mouse 
between cKO and WT group. A contextual fear conditioning (CFC) test was supposed 
to indicate the potential of cKO mice to consolidate long-term memories and it is known 
to be hippocampus dependent. However, we observed the very interesting phenomenon of 
cKO mice showing very low level of motility in the chamber even before the electric 
current was applied (see Fig.4D). This made it impossible to make proper conclusions 
about the freezing response 24h after subjecting animals to electric shocks and therefore 
access memory impairment, but it was an interesting observation per se which we have 
never observed before in our laboratory.  The prepulse inhibition (PPI) of acoustic startle 
response is homologous in humans and rodents and is known to be impaired in many 
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schizophrenic patients and mouse models of schizophrenia167. The PPI concept is that 
weak sensory stimulus (“prepulse”) applied shortly before the strong stimulus (“pulse”) 
suppresses a startle reflex. It is considered to indicate sensorimotor gating, a way of 
inhibiting irrelevant sensory signals in CNS during the early processing steps, so that the 
organism can direct its attention towards more important signals. We did not reveal 
significant difference between cKO and WT group in PPI task, indicating that attenuation 
of motor response to a startling sound was not deregulated (see Fig.4F). However, the 
startle response itself among cKO was twice as high as in WT animals (see Fig.4E). 
Sensory gating defects and, as an outcome, hypersensitivity to a pre-stimulus has been 
also observed in individuals with ASD168. Increased startle amplitude has been previously 
observed in the autism mouse model with the loss-of-function in the gene coding glutamate 
ionotropic receptor NMDA type subunit 1 (Grin1)169 and reduced levels of nSR100 splicing 
regulator170. Most probably, in our case increased baseline startle is observed due to startle 
response modulation from the cortex, where Setd1b is gone from the excitatory neurons. 
In all above-mentioned tests Setd1b WT and cKO male and female mice were tested 
together and showed the same trends and no sex-specific effects or sex-genotype 
interactions were detected.    
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Figure 2-6 Non-affected behaviors upon Setd1b loss. (A) Time spent in the center of open field did not 
differ among two groups (WT: n=15, cKO: n=15; Student t-test: p-value=0.9574). (B) Total distance 
travelled in OF was similar between WT and cKO (WT: n=15, cKO: n=15; Student t-test: p-value=0.0763). 
(C) Speed in the OF was similar between two groups (WT: n=15, cKO: n=15; Student t-test: p-
value=0.0749). (D) Working memory is not changed in Y-maze test maze in cKO group (WT: n=15, cKO: 
n=15; Student t-test: p-value=0.299). (E) No changes in short-term memory test of novel object recognition 
(WT: n=15, cKO: n=15; Student t-test: p-value=0.766). (F) Depression phenotype is absent according to 
tail suspension test (WT: n=8, cKO: n=8; Student t-test: p-value=0.897). (G) Setd1b cKO do not differ in 
time spent near stranger mouse in social novelty test (WT: n=15, cKO: n=15; Student t-test: p-




To exclude the effect of cre-insertion under CamKII promoter in our cKO group to the 
above-mentioned behaviors we have subjected cre+ (n=8) and cre- (n=8) animals of 
transgenic CamKII line. We have shown that CamKII-promoter controlled Cre-expressing 
mice did not have reduction of body weight and did not show any anomalies in behavioral 
testing when compared to control animals (see Supp.Fig.1), including the most severe 
Setd1b phenotypes such as basal freezing in fear conditioning (see Supp.Fig.1H) and 
MWM (see Supp.Fig.1D,E,F,G). Cre+ mice also did proper nests (data not shown).  
 
In summary, we performed profound behavioral characterization of mice with postnatal 
neuronal loss of Setd1b histone methyltransferase from the forebrain excitatory neurons. 
Setd1b deficient mice and their wild-type littermates showed no differences in the open 
field test, Y-maze, novel object recognition, tail suspension and social novelty test. 
However, cKO animals showed aberrant cognitive phenotype in Morris water maze, basal 
freezing in contextual fear conditioning, acoustic startle response, rotarod motor learning, 
nest building and elevated-plus maze. Behavioral alterations observed are most probably 
not related to gross morphology changes, since we did not observe any (see Fig.2C,D).     
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4.4. Setd1b epigenetic and RNA regulatory neuronal functions  
 
After the identification of impaired hippocampal learning, memory formation and 
cognitive disabilities in Setd1b cKO mice, we wanted to unravel the processes by which 
Setd1b influences memory formation in molecular detail. For this endeavor, we have 
investigated the epigenetic influence on gene expression in hippocampal neurons. Prior to 
this study, we have accessed transcriptomics of CA and DG of Setd1b cKO animals with 
the whole tissue RNA-seq (see Supp.Fig.5). Later, in our laboratory we have developed a 
more precise way of analyzing gene expression changes in neuronal cells only, which we 
utilized in this study for the first time. Hippocampal tissue of the CA region was obtained 
via microdissection from Setd1b cKO and WT animals and neuronal cells were isolated 
through anti-NeuN antibody mediated FACS (see Fig.7A-C). Nuclei were then prepared 
of the sorted cells, which were then used to perform neuron-specific chromatin-
immunoprecipitation (ChIP) and RNA-seq, generating two different datasets from the 
same mouse brain tissue (courtesy of Sakib Sadman and Dr. Cemil Kerimoglu). Specificity 
of the anti-NeuN antibody for neuronal cells was validated through specifically enriched 
genes in the RNA-seq and GO-term analysis (see Fig.7D,E). Genes specific for neuronal 
(see Fig.7F) and glial cells (see Fig.7G) were further quantified for validation of the 
neuronal specificity of NeuN+ mediated FACS.  
 
For the ChIP experiments, we have analyzed the histone modifications H3K4me3, 
H3K4me1, H3K9ac and H3K27ac. H3K4me3, a marker for active genes and transcription 
start sites (TSS), was chosen as Setd1b is a H3K4 methyltransferase, with H3K4me1 being 
an intermediate transitional state171. H3K9ac has been reported to be associated with 
H3K4me377,78, and H3K27ac modification is enriched at active gene TSS and enhancer 
regions172, with no direct correlation to H3K4me3. As a result, H3K4me3 levels are 
significantly decreased in neuronal nuclei of Setd1b cKO mice throughout the genome, 
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and the majority of changed H3K4me3 modifications occur at TSS regions (see Fig.8A,B). 
The same could be observed for the H3K9ac and H3K27ac epigenetic modifications, 
however to a lesser extent than H3K4me3 (see Fig.8C). H3K4me1 levels were also 
significantly changed in Setd1b cKO neurons, but in contrast to the H3K27ac 
modifications, it was increased in the proximity of TSS (see Fig.8A, B). Further analysis 
showed, that of the four epigenetic marks, H3K4me3 is the most affected histone 
modification in the proximity of TSS (see Fig.8D). In addition and as previously reported, 
H3K4me3 can be functionally linked to H3K9ac77,78, as the genes affected exhibit a major 
overlap (see Fig.8E), while the H3K27ac epigenetic mark does not. Total numbers of 






Figure 2-7 Neuronal specific nuclei sorting for ChIP and RNA-seq. (A) Experimental pipeline for cell-
type specific ChIP-seq and RNA-seq. For Chip-seq we sacrificed 4 control and 4 Setd1b cKO mice. (B) 
Representative images showing nuclei that were sorted using the neuronal marker NeuN. Scale bar: 50μm. 
(C) Gating strategy for sorted NeuN(+) and NeuN(-) nuclei. (D) RNA-seq (n=2/group) was performed 
from NeuN(+) and NeuN(-) nuclei and a differential expression analysis was performed. Heat map shows 
836 genes specifically enriched in NeuN(+) nuclei when compared to NeuN(-) nuclei. The criteria to select 
those genes were: adjusted p-value <0.01, base mean > 150, fold change > 5. (E) GO-term analysis showing 
that the top 10 enriched biological processes and molecular functions for the 836 genes enriched in NeuN(+) 
nuclei all represent specific neuronal processes. (F) Normalized expression values obtained from the RNA-
seq experiment showing the expression of selected genes known to be enriched in neurons. (G) Normalized 
expression values of genes that are known to be enriched in non-neuronal cells including glia cells. Error 
bars indicate SEM. (A-G) are courtesy of Sakib Sadman. 
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Most interestingly, H3K4me3 decrease in Setd1b cKO neurons is the most prominent 
downstream of TSS, effectively influencing the width of the epigenetic mark at the site 
(see Fig.8F). Further analysis revealed, that this reduced peak width was most prominent 
in genes which exhibited both a decrease in H3K4me3 and an increase in H3K4me1 (see 
Fig.8G), when compared to genes where only H3K4me3 was decreased (see Fig.8H). Broad 
H3K4me3 peaks are correlated with very stable gene expression levels and cellular 
identity173. We have therefore checked genes sorted by H3K4me3 peak width at TSS for 
increased H3K4me1, and indeed, genes with already broad H3K4me3 peaks exhibit 
increased H3K4me1 levels in the proximity of TSS in Setd1b cKO mice (see Fig.8I). 
Furthermore, the genes that have a broad H3K4me3 peak are also expressed at a higher 
rate by default (see Fig.8J). Functional analysis revealed that the genes with elevated 
H3K4me3 levels at the TSS in Setd1b cKO mice are indeed genes associated with specific 
neuronal identity and functions in hippocampal excitatory neurons (see Supp.Fig.8). 
Taken together, Setd1b seems to play a crucial role for neuronal identity, learning and 
memory formation, through its histone methylation function, in hippocampal neurons of 
the mouse.  
 
Analysis of the RNA-seq data of Setd1b cKO mouse sorted nuclei of the CA region 
revealed, that indeed the majority of affected genes is downregulated (see Fig.9A), and 
that downregulated genes are indeed associated with decreased H3K4me3 peak width and 
elevated H3K4me1 around the TSS (see Fig.9B,C). As a control, genes unaffected by 
Setd1b exhibited normal H3K4me3 peak width and no enrichment of the H3K4me1 
epigenetic modification, when compared to control animal RNA-seq results (see Fig.9D). 
As described above, genes affected by the Setd1b cKO normally have a broader H3K4me3 
peak width and are expressed at higher rates than genes not impacted by Setd1b (see 
Fig.9E). A GO functional analysis confirmed the previous finding, that Setd1b regulated 
genes are active in synaptic plasticity and cognitive function pathways (see Fig.9F). In 
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summary, our RNA-seq data also suggests, that Setd1b regulates a subset of genes, which 
are characterized by broad H3K4me3 peak width, are highly expressed at basal levels, and 




Figure 2-8 Setd1b controls histone-methylation and H3K4me3 peak width. (A) Left: Genes with 
significant differential H3K4me3 levels at TSS (+/-2kb) in Setd1b cKO compared to wildtype mice and 
overall loci with altered H3K4me3. Right: Similar analysis for H3K4me1 (FDR<0.05 & |fold change|>1.5). 
(B) Number of genes with decreased and increased H3K4me3 and H3K4me1 levels at TSS in Setd1b cKO 
mice (FDR<0.05 & |fold change|>1.5). (C) Left: Genes with differential H3K9ac at TSS in Setd1b cKO 
mice. Right: Similar analysis for H3K27ac levels. (D) Genes with decreased and increased H3K4me3, 
H3K4me1, H3K9ac and H3K27ac levels at TSS. (E) Decreased H3K9ac, but not H3K27ac at the TSS 
correlates with reduced H3K4me3 levels. (F) NGS plot showing reduced H3K4me3 peak width in Setd1b 
cKO mice at TSS. Right: Reduced H3K4me3 in Setd1b cKO mice is mainly occurring downstream of TSS 
(*** Student t-test p-value < 0.001). (G) NGS plots showing H3K4me3 and H3K4me1 at TSS of genes 
which show significantly reduced H3K4me3 and increased H3K4me1 in Setd1b cKO mice. Right panel shows 
quantification (Student t-test: ** p-value < 0.01, **** p-value < 0.0001). (H) NGS plot showing H3K4me3 
and H3K4me1 at TSS of genes that show both reduced H3K4me3 and H3K4me1 in Setd1b cKO mice. Right 
panel shows quantification (Student t-test: * p-value < 0.05, **** p-value < 0.0001). (I) Left: Basal 
H3K4me3 peak width for genes characterized by decreased H3K4me3 in combination with either increased 
or decreased H3K4me1 in Setd1b cKO mice. Right: Peak width quantification of genes with decreased 
H3K4me3 in combination with either increased, decreased or not altered H3K4me1 in Setd1b cKO mice 
(One-way ANOVA: p-value < 0.0001. Post-hoc multiple comparisons, Tukey’s test: increased H3K4me1 vs 
no change H3K4me1, **** p-value < 0.0001; increased H3K4me1 vs decreased H3K4me1, **** p-value < 
0.0001; no change H3K4me1 vs decreased H3K4me1, §§§§ p-value < 0.0001). (J) Basal wild type expression 
levels of genes that display altered H3K4me3 in Setd1b cKO mice. (One-way ANOVA: p-value < 0.0001. 
Post-hoc multiple comparisons, Tukey’s test: increased H3K4me1 vs no change H3K4me1, **** p-value < 
0.0001; increased H3K4me1 vs decreased H3K4me1, **** p-value < 0.0001; no change H3K4me1 vs 















Figure 2-9 Setd1b controls highly expressed genes correlated with learning and memory which exhibit 
broad H3K4me3 peaks. (A) Genes differentially expressed in hippocampal neurons of Setd1b cKO mice. 
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n=3. (B) H3K4me3 peak width is significantly decreased in Setd1b cKO mice, but there is a marked increase 
of H3K4me1 at the TSS of the example gene Arpp21 in Setd1b cKO mice. (C) NGS plots showing H3K4me3 
and H3K4me1 at TSS of downregulated genes in Setd1b cKO mice. Right panel shows quantification. (D) 
NGS plots showing H3K4me3 and H3K4me1 at TSS of genes that were not altered in Setd1b cKO mice. 
Right panel shows quantification. (E) Left: H3K4me3 peak width is significantly broader in downregulated 
genes, when compared to genes that were unaffected in Setd1b cKO mice. Right: Genes downregulated in 
Setd1b cKO mice exhibit a higher baseline expression when compared to genes that were unaffected. (F) 
Heat map showing functional pathways affected by downregulated genes in Setd1b cKO mice. Error bars 
indicate SEM. Student t-test: * p-value < 0.05, **** p-value < 0.0001. (A-F) are courtesy of Dr. Cemil 
Kerimoglu. 
 
4.5. Setd1b specifically regulates highly expressed genes with neuronal functions, 
which exhibit broad H3K4me3 peak width 
 
To evaluate the specificity of Setd1b function among other H3K4 methyltransferases, we 
have compared our Setd1b cKO ChIP datasets with H3K4me3 and H3K4me1 ChIP-seq 
data of cKO mice, in which Kmt2a or Kmt2b have been conditionally knocked out in 
excitatory neurons of the forebrain78. As expected, cKO of the different H3K4 
methyltransferases decreased H3K4me3 at TSS in a number of genes in all three datasets 
(see Fig.10A), but interestingly, only Setd1b cKO induced H3K4me1 accumulation at TSS 
in a significant subset of genes (see Fig.10B). Furthermore, the subsets of genes with 
decreased H3K4me3 did not overlap among the three different datasets to a greater extent, 
suggesting that Kmt2a, Kmt2b and Setd1b each have specific regulatory functions in 
excitatory neurons of the mouse forebrain (see Fig.10C). Interestingly, among these three 
enzymes, Setd1b was the only one who regulated only 25% of trimethylation in the TSS 
(+/-1kb) regions, while Kmt2a and Kmt2b regulated 84% and 61% correspondingly (see 
Supp.Fig.7). To further investigate this finding, we have compared gene expression 
changes in whole tissue RNA-seq datasets of the hippocampal CA region of Kmt2a, Kmt2b 
and Setd1b cKO mice. There was again not a large overlap of downregulated genes, further 
suggesting specific functions in each of the three H3K4 methyltransferases in the mouse 
forebrain (see Fig.10D and Fig.12B). In more details this will be discussed in the Results 
4.7 section. Also, GO term analysis again confirmed genes impacted by Setd1b cKO to be 
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involved in neuronal identity pathways, which was not the case for the Kmt2a and Kmt2b 
datasets (see Fig.10E). Comparative analysis with the ChIP data revealed, that genes 
decreased in expression in each of the H3K4 methyltransferases also displayed decreased 
H3K4me3 at TSS, but only Setd1b exhibited additional accumulation of H3K4me1 at 
these TSS (see Fig.10F). Further investigations revealed genes affected by Setd1b to have 
broader H3K4me3 peaks at TSS (see Fig.10G) and higher gene expression levels (see 
Fig.10H) in normal conditions, when compared to genes impacted by either Kmt2a or 
Kmt2b cKO. Similar to the NeuN+ RNA-seq, GO term analysis showed Setd1b regulated 
genes to be associated with learning, memory formation and hippocampal neuronal 
functions (see Fig.10I). Taken together, Setd1b is important for hippocampal neuronal 








                         
 
Figure 2-10 Comparative analysis of the hippocampal transcriptomes in Setd1b, Kmt2a and Kmt2b 
cKO mice. (A) Number of genes with significantly altered H3K4me3 at TSS (Kmt2a: control, n = 5; cKO, 
n = 3. Kmt2b: control, n = 6; cKO, n = 5. Setd1b: control, n = 4; cKO, n = 4). (B) Number of genes with 
significantly altered H3K4me1 at TSS. (C) Overlap of genes with significantly decreased H3K4me3 at TSS 
among Kmt2a, Kmt2b and Setd1b cKO mice. (D) Number of differentially expressed genes from RNA-seq 











= 11. Setd1b: control, n = 6; cKO, n = 6). (E) Downregulated genes with decreased H3K4me3 were tested 
for overlap with 836 neuronal identity genes defined earlier for the hippocampal CA region (see Fig.7D). 
(F) Left: H3K4me3 binding around TSS of downregulated genes exhibiting significantly decreased H3K4me3 
in the three respective cKO mice (Two-way ANOVA: * p-value < 0.05, *** p-value < 0.001). Right: 
H3K4me1 for the same TSS regions as for H3K4me3 (Two-way ANOVA **** p-value < 0.0001). (G) Genes 
exhibiting decreased H3K4me3 and reduced expression in Kmt2a, Kmt2b or Setd1b cKO mice were analyzed 
for H3K4me3 peak-width at TSS. (H) Basal expression levels of genes downregulated with decreased 
H3K4me3 at the TSS in Kmt2a, Kmt2b or Setd1b cKO mice. (I) Heat map showing functional pathways 
of genes affected in Kmt2a, Kmt2b or Setd1b cKO mice. Error bars indicate SEM. (A-I) are courtesy of Dr. 
Cemil Kerimoglu.  
 
4.6. Setd1b conveys specific functions in a subset of neurons as revealed by single 
cell sequencing analysis 
 
Among the H3K4 methyltransferases in the mouse forebrain, according to our NeuN+ 
RNA-seq data, Setd1b is significantly less expressed in comparison to Kmt2a or Kmt2b 
(see Fig.11A). Setd1b is therefore either uniformly expressed at lower levels in all neurons, 
or not all cells express Setd1b, a hypothesis that cannot be addressed by our NeuN+ 
RNA-seq data performed on total brain tissue of the CA region. To address this question, 
we have performed single cell sequencing on NeuN+ FACS sorted cell nuclei (see Fig.7A). 
As a result, we obtained sequencing data of CA region specific excitatory neurons, 
neuronal cells specific to the dentate gyrus and also inhibitory neurons (see Fig.11B). The 
dataset of excitatory neurons was taken and expression levels of Kmt2a, Kmt2b and 
Setd1b were analyzed. As a result, Kmt2a was uniformly expressed among all sequenced 
nuclei (see Fig.11C), whereas Kmt2b and Setd1b, with the expression of all three 
methyltransferases being at a comparable level (see Fig.11D), were only expressed in a 
subset of cells (see Fig.11E). This finding explains the discrepancy found in the bulk RNA-
seq data obtained from CA tissue, and confirms the hypothesis, that Setd1b is expressed 
only in a subset of selected neurons in the CA region. Most interestingly, when comparing 
the datasets of nuclei expressing exclusively Kmt2a, Kmt2b and Setd1b with each other, 
Kmt2a seems to specifically increase expression of 897 genes, whereas 432 genes were 
specifically upregulated by Kmt2b and 214 genes by Setd1b (see Fig.11F). Although 
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Setd1b is expressed in the smallest faction of nuclei and upregulates the smallest subset 
of genes, when compared to Kmt2a and Kmt2b, but its impact on the upregulation of 
gene expression is the strongest with 66% and 1,5x higher upregulation vs. Kmt2a 7% and 
Kmt2b 41% (see Fig.11F). GO term analysis of the dataset revealed that genes 
upregulated by Setd1b function in pathways linked to hippocampal function and histone 
acetylation, whereas Km2ta and Kmt2b impact these pathways to a much lesser extent 
(see Fig.11G). In summary, Setd1b function in the hippocampus seems to intimately be 
linked to neuronal identity, and the subset of Setd1b expressing neurons, when compared 
to Kmt2a and Kmt2b expressing cells, might have a pivotal impact on neuronal plasticity 
through a stronger impact on gene expression and specific activation of hippocampal and 













Figure 2-11 Setd1b functions are distinct to Kmt2a and Kmt2b as revealed by single cell sequencing 
data analysis. (A) Expression of Kmt2a, Kmt2b and Setd1b in neuronal nuclei from the hippocampal CA 
region (n = 3798). (B) UMAP plot showing the data from 3798 neuronal nuclei. (C) UMAP plot showing 
the clustering of 2619 nuclei from hippocampal excitatory neurons from the CA region indicating the 
normalized expression of Setd1b, Kmt2a and Kmt2b. (D) Normalized expression of Kmt2a, Kmt2b and 
Setd1b in respective positive cells. (E) Number of nuclei positive for Kmt2a, Kmt2b or Setd1b. (F) 
Differential expression analysis for Kmt2a, Kmt2b and Setd1b positive nuclei vs. negative nuclei. Left: Fold 
change of genes significantly increased in either Kmt2a, Kmt2b or Setd1b positive nuclei. Right: Comparison 
of genes significantly increased in Kmt2a, Kmt2b or Setd1b positive nuclei with a fold change above 1.5 
(upper diagram) or below a fold change of 1.5 (lower diagram). (G) Top GO and Kegg pathways representing 
the genes increased in Setd1b positive nuclei. (A-G) are courtesy of Dr. Cemil Kerimoglu and Dr. Dennis 
Krüger. 
 
4.7. Differences and similarities between different KMT cKOs 
 
We have previously studied Kmt2a and Kmt2b cKO mice, where the ablation of 
methyltransferases was generated in a similar manner to Setd1b as previously shown. We 
are now able to analyze the similarities and differences between behaviors (see Tabl. 14) 
and try to correspond them to the altered transcriptome and trimethylation data for all 
three enzyme datasets. 
 
Kmt2a conditional knock-out mice also failed to build nests, had impaired spatial memory 
and increased anxiety in the open field test and light-dark box test174. Furthermore, as 
revealed in a study of our group, Kmt2a cKO had poor performance in the contextual fear 
conditioning, Morris water maze and decreased anxiety behavior in the elevated plus 
maze78. Of note, viral ablation of Kmt2a from the excitatory neurons of the striatal area 
induced pro-depressant (tail suspension test and forced swimming test) and anxiogenic 
behavior (elevated plus maze)175. Kmt2b loss affected hippocampus-dependent memory 
based on contextual fear conditioning and novel object recognition and performance during 
the probe test of MWM77. 
  
 84 
Kmt2a and Setd1b 
similarity 
Kmt2a cKO only Setd1b only 
- Absent nesting behavior*174  
- More time in the open arms 
of EPM78 
- Spatial memory 
impairment in MWM78 
 
- Impaired learning in CFC78 
- Increased anxiety in OF and 
light-dark box*174 
- Spatial memory impairment 




- Increased basal freezing 
in CFC 
- Increased acoustic 
startle response 
- Avoidance of closed 
arms in EPM/more time 
in the open arms 
- Disturbed learning in 
rotarod (was tested in 
Kmt2a cKO and not 
affected*)174 
Kmt2b and Setd1b 
similarity 
Kmt2b cKO only 
- Spatial memory 
impairment in MWM during 
probe test77 
 
- Increased anxiety in OF and 
EPM175 
- Impaired learning in NOR 
- Impaired learning in CFC77 
 
Table 14: Comparative analysis of behaviors observed among Kmt2a, Kmt2b and 
Setd1b cKO (*marked results are originating from observation of another scientific 
group who used the same mouse model but accessed behaviors through different tests). 
 
Disturbed performance in MWM test is the only uniting behavioral phenotype among 
Kmt2a, Kmt2b and Setd1b observed in our group. We have plotted MWM data previously 
generated in our laboratory with the same experimental protocol for Kmt2a and Kmt2b 
against newly obtained Setd1b data as normalized to the corresponding control escape 
latency (See Fig.12A). Setd1b cKO animals have the most severe learning impairment 
among three KMT cKOs. The degree of spatial memory impairment seems to be 
corresponding with the obtained gene expression data, in which Setd1b appeared to be 
the most crucial regulator for neuronal identity, learning and memory formation in 
comparison of all three KMTs, while Kmt2a loss affected more general cellular pathways 
together with neuronal function genes. Kmt2b mice, who had the mildest impairment of 
spatial learning, did have deficits during the probe test77 and correspondingly affected 
genes not specific to brain function. 
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Since all three KMT cKOs are associated with a widely deregulated hippocampal 
transcriptome, which was accessed by the whole tissue CA-region RNA-seq, we have 
plotted the Venn-diagrams of down- and upregulated genes (see Fig.12B,C). Even though 
Kmt2a and Kmt2b are orthologues closely related to each other, we see that genes 
deregulated upon the respective loss are very different and barely overlap, which is the 
same for Setd1b cKO data (see Table 15). The only transcript differentially expressed for 
all three enzymes was the Oxidation Resistance 1 gene (Oxr1). 
 
Group Total Downregulated genes Total Upregulated genes 
Kmt2a/Setd1b 43 Thsd4, Spink8, Serpina3n, 
Zbtb20, Glt8d2, Fam84b, 
Amigo2, Skida1, Nrp1, 
Synpr, Lefty1, Map4, 
Apln, Ppapdc2, Hdac9, 
Klhl13, Myo5b, Dnah9, 
Acan, Wfs1, Epha6, 
Strip2, Nr3c2, Gm2115, 
Dmd, Cbfb, Gabra5, 
Mctp1, Lix1, Aqp4, Ccbe1, 
Ugt8a, Fgfr1, Dock11, 
Ednrb, Robo1, Zdhhc23, 
Bcl6, Tmem229a, Zeb2, 
Nbl1, Sema3e, Oxr1 
1 Grasp 
Kmt2b/Setd1b 19 Kl, Col11a1, Grem1, 
Drd1a, Tmem255a, 
Gpr165, Gdf10, Tusc1, 
Rab27a, Marcksl1, 
Gm12462, Hcrtr1, Doc2a, 
Tuft1, Pmaip1, Rimklb, 
Slc29a4, 1110032F04Rik, 
Oxr1 
3 Obscn, Gm3693, 
8030453O22Rik 
 
Kmt2a/Kmt2b/Setd1b 1 Oxr1 0  
Table 15: Overlapping differentially expressed genes for Kmt2a, Kmt2b and Setd1b 






Figure 2-12 Comparison of performance in MWM and gene expression of Kmt2a, Kmt2b and Setd1b 
cKO. (A) Escape latencies of Kmta, Kmt2b and Setd1b cKO mice in Morris water maze revealing differences 
in spatial learning between KMT knock-outs. Time required to reach the platform for KO animals was 
normalized to corresponding control group. Increase of normalized escape latency indicates shows the 
difference between cKO and corresponding control group, thus showing that Setd1b cKO have the poorest 
performance in spatial learning. (Setd1b cKO, n=14 vs Kmt2a cKO, n=13: Repeated measures ANOVA, 
genotype effect: F(1,25)=16.83, *** p-value<0.001; Setd1b cKO, n=14 vs Kmt2b cKO, n=22: Repeated 
measures ANOVA, genotype effect: F(1,34)=70.66, **** p-value < 0.0001). Error bars indicate SEM. (B) 
Genes downregulated and upregulated (C) in the whole-tissue CA-region RNA-seq of Kmta, Kmt2b and 
Setd1b cKO, fold change>1.2, padj<0.1. (D) Decreased expression in NeuN+ RNA-seq and decreased 
H3K4me3 and H3K9ac peaks of the only overlapping gene between all three cKO, Oxr1 (IGB profile). 
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The role in neuronal functions of the closest homologue of Setd1b, Setd1a, has been 
investigated due to the connection of its loss of function with schizophrenia176. In the study 
a transcriptomic dataset from the PFC region of a Setd1a heterozygous loss-of-function 
mouse model was analyzed. Mice did not exhibit any abnormalities in the open field test, 
novel object recognition, fear conditioning and social memory, but had impairment in the 
working memory according to a T-maze delayed non-match to place. We found that only 
10 genes were overlapping between the two Setd1 cKO models, and Oxr1 was not found 
among them (see Supp.Fig.9). We therefore conclude that the Setd1 orthologues regulate 
distinct sets of target genes. 
 
Mice with heterozygous mutations in the Kmt2d have deficits in novel object recognition, 
probe test of Morris water maze and contextual fear conditioning, indicating hippocampal 
memory disfunction89. They also had deficiency in the bulk levels of H4K4me3 in the 
hippocampus and reduced neurogenesis levels. There are no studies showing the role of 
Kmt2c in the mouse brain and corresponding phenotype, even though a loss of function 
in humans is associated with intellectual disability and the Kleefstra syndrome87. Taken 
together, we show for the first time a transciptopathy and mental retardation associated 
with the loss of Setd1b in the adult murine brain, which has not been previously described 
in the mouse model. Our data and the published literature indicate KMTs to play non-
redundant roles in the gene expression and behavior. 
 
4.8. The HDAC inhibitor SAHA does not restore cognitive functions in Setd1b 
cKO mice 
 
It has been previously reported, that the inhibition of HDAC enzymes can improve 
learning and memory formation in cognitively impaired mice102. As we also observed a loss 
of histone acetylation in the Setd1b cKO mice, we have tried to rescue their cognitive 
performance in behavioral experiments by the application of the HDAC inhibitor 
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Vorinostat111,112 into the animal drinking water. We have treated four groups of animals 
in total: WT and cKO receiving SAHA, and WT and cKO treated with vehicles as 
corresponding controls. After four weeks of treatment, Setd1b cKO mice were subjected 
to the MWM behavioral experiment (see Fig.13). Interestingly, after 5 days of training 
we observed the improvement of learning speed among the SAHA treated cKO group 
compared to vehicle treated (see Fig.13A), therefore, we performed the first probe test. 
We clearly saw the trend of increased number of visits to the control region and to the 
target quadrant, as well as in the % of time spent in those areas (see Fig.13B-E) among 
SAHA treated cKO group, but none of them we significant according to Student’s t-test. 
Surprisingly, after conducting the probe test, improvement of learning among SAHA 
treated cKO mice was diminished (see Fig.13A). After 4 more days of learning, we 
subjected animals to the second PT. None of the read-outs for memory retrieval showed 
anymore difference between SAHA and vehicle treated cKO animals and the trend we 
observed during the PT1 was also gone (see Fig.13F-I). Search strategies used by two 






Figure 2-13 SAHA effect on the spatial memory impairment of Setd1b cKO in Morris water maze. (A) 
Escape latency during MWM (two-way-ANOVA, treatment effect for KO_S vs KO_V: F (1,18)=1.965, p-
value=0.1780). (B) Visits to target zone on PT1 (p-value=0.4817). (C) % of time spent in the target zone 
on the PT1 (p-value=0.6524). (D) Visits to target quadrant on PT1 (p-value=0.2171). (E) % Time spent 
in the target quadrant during the PT1 (p-value=0.1513). (F) Visits to target zone on PT2 (p-value=0.5151). 
(G) % of time spent in the target zone on the PT2 (p-value=0.4684). (H) Visits to target quadrant on PT2 
(p-value=0.4001). (I) % Time spent in the target quadrant during the PT2 (p-value=0.7352). (K) Search 
strategies of cKO animals treated with SAHA (n=5) vs vehicle (n=6). For all graphs WT_SAHA: n=13, 
cKO_SAHA: n=9; WT_Vehicle: n=11; cKO_Vehicle n=11 and Student’s t-test p-values are indicated for 






4.9. Mouse model of IGFBP7 liver overexpression 
To evaluate whether increased blood levels of IGFBP7 would affect cognition and cause 
AD-like phenotype, we have crossed mice containing with stop-codon surrounded by loxP 
sites in front extra IGFBP7 allele in Rosa26 locus with animals expressing cre-recombinase 
under liver-specific albumin promoter (see Fig.14A). Prerequisite of this study was the 
data generated in our group showing increased levels of IGFBP7 in the plasma of AD 
patients (see Fig.14B). Mice did not differ in their weight (see Fig.14C) or physical 
appearance (data not shown). We have observed 3-fold increase of IGFBP7 mRNA levels 
in liver tissue, verifying the validity of our model, while hippocampal levels in CA and 
DG were not affected (see Fig.14D,E,F). We have tested two different antibodies to 
evaluate protein levels in the liver, but they were not specific (data not shown). 
Fig. 14 
              
Figure 2-14 Modelling human plasma elevation of IGFBP7 in mice. (A) Principle of generation liver-
originating IGFBP7 overexpression mouse line. (B) Elevated concentrations of IGFBP7 in plasma of AD 
patients. (C) Weight of IGFBP7-albCre mice is not changed (WTA: n=9, WTB: n=9; KI: n=9; Student t-
test). (D) mRNA level of IGFBP7 is decreased in the liver tissue of KI mice but not in the wild-types 
(WTA) (WT: n=6, KI: n=6; Student t-test: *** p-value < 0.001). (E) mRNA levels of IGFBP7 do not 
differ in CA region and (F) DG region of animals with liver overexpression of IGFBP7 (WT: n=6, KI: n=6; 
Student t-test: p-value=0.5943 and 0.6434 accordingly). Error bars indicate SEM. 
A 
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5. Peripheral increase of IGFBP7 does not cause memory deficits 
 
To test the behavioral effects of IGFBP7 overexpression originating from liver, we 
subjected three months old animals to the standard behavioral battery. In order to exclude 
the effect of genetic constructions of two lines used to generate knock-in line, we subject 
to testing all three groups, WTA (mice with cre-recombinase under albumin promoter in 
liver), WTB (mice with inactivated IGFBP7 allele in ROSA26 locus) and KI (extra 
IGFBP7 gene is activated in ROSA26 locus in albumin expressing liver cells). 
Groups did not differ in the speed and distance travelled in the open field test, indicating 
the absence of major motor disability (see Fig.15A,B). Explorative behavior was similar 
between WT groups and KI based on the time spent in the center of the open field (see 
Fig.15C).  
We did not observe genotype effect in the elevated plus maze, aimed at recognizing 
anxiety levels and exploratory behavior (see Fig.15D,E). Both groups spent comparable 
amount of time in the closed arms or center region. Subsequently, no difference was 
observed in the time spent in open arms. 
Novel object recognition paradigm was used to evaluate deficits in long-term recognition 
memory. All three groups spent comparable amount of time near new object in the novel 
object recognition test (see Fig.15F). 
 
Since Alzheimer’s disease is characterized by gradual loss of memory, we have accessed 
spatial memory performance in Morris water maze test, highly dependent on hippocampus. 
Many AD mouse models exhibit memory impairment at the different age, including spatial 
memory impairment177,178,179. All three groups reached the learning plateau on the 4th and 
5th day, indicating fast memory acquisition (see Fig. 16A), therefore, we conducted the 
first probe test after 5th day. No significant differences between groups was detected 
neither in the numbers of visits to the removed platform area and quadrant, where the 
platform used to be located (see Fig.16C,D), nor in the amount of time they spent in the 
 92 
area of platform (see Fig.16E,F). Same was observed for the second PT conducted after 
three additional days of learning. Groups did not show any difference in the swim speed 
on the very first trying (see Fig.16K), additionally proving the absence of major motor 
impairment. Strategies used for all three groups to find a hidden platform we similar and 
progressed with the same trend for WTs and KI (see Fig.16B) 
 
In order to see whether cognitive phenotype develops negatively with a time, we tested 
the animals three months later, when they were six months old. We used the reversal 
learning concept in MWM, when the location of hidden platform is changed comparing to 
the former MWM testing. Already on the 1st day all three groups were identifying platform 
location within 20 seconds (see Fig.17A) and during PT conducted after 5 days of learning 




















       
 
Figure 2-15 Increase of liver-originated IGFBP7 does not affect basic behaviors in mice. (A) Speed in 
the open field, (B) total distance travelled and (C) % of time in the center did not differ between the groups. 
(D) % of time spent in the open arms as well as closed arms (E) of elevated plus maze was not affected by 
KI of IGFBP7. (F) Novel object recognition test did not reveal any differences between the groups. In all 






             
 
Figure 2-16 Spatial memory is not impaired in 3 months old mice with IGFBP7 overexpression in 
Morris water maze test. (A) Platform learning curves were similar between KI and WT groups (two-way-
ANOVA, genotype effect: WTA vs KI F(1,16)=1.19; p-value=0.2897; WTB vs KI F(1,16)=0.16; p-
value=0.6887). (B) We did not observe any differences between the strategy selected and distribution of 
strategies corresponded to normal hippocampal functions. (C) First probe test performed after day 5 of 
training did not reveal any changes in the number of visits in target quadrant (B), in platform area (C) as 
well as % of time spent in both of those areas (E, F). Same trend we observed for the second probe test, 
performed after day 8 of training (G, H, I, J). (K) Swimming speed on the very first trial of the first day of 
learning was the same among groups. In all experiments WTA: n=9, WTB: n=9; KI: n=9; Student t-test 
if not indicated; Error bars indicate SEM.  
Fig. 16A 




Figure 2-17 Spatial memory is not impaired in 6 months old mice with IGFBP7 overexpression in 
longitudinal Morris water maze test. (A) Escape latencies did not differ between KI and both WT groups 
(two-way-ANOVA, genotype effect: WTA vs KI F (1,16)=0.39; p-value=0.5435; WTB vs KI F (1,16)=0.11; 
p-value=0.7354). (B) Neither number of visits in target quadrant, nor in platform area (C) as well as % of 
time spent in both of those areas (D, E) had differences. In all experiments WTA: n=9, WTB: n=9; KI: 







In this work, we have shown that Setd1b loss of function in excitatory neurons of the 
mouse forebrain results in severe learning and memory formation impairments and few 
other behavioral deficits. Subsequent molecular workup with RNA-seq and ChIP-seq 
approaches revealed, that Setd1b indeed regulates highly expressed genes for neuronal 
identity and cognitive functions on the epigenetic and on gene expression levels, in a 
distinct manner to the other H3K4 methyltransferases Kmt2a and Kmt2b.  
 
6.1. Benefits and drawbacks of the Setd1b-CaMKII-Cre mouse model 
 
One obvious benefit of the Setd1b-CaMKII-Cre mouse is its completion of embryonic 
development and survival in adulthood, as Setd1b unconditional knockout mice die after 
gastrulation122 and conditional knockout mice die after 30 weeks2. This Setd1b induced 
lethality was successfully circumvented by creating the Setd1b-CaMKII-Cre mouse with 
a Cre-controlled Setd1b122 and a Cre-recombinase restricted to the mouse forebrain123. 
Furthermore, cognitive impairments cannot be attributed to developmental alterations, 
as Setd1b is only deleted 3 weeks after the animals were born, and no structural brain 
abnormalities have been observed (see Fig.2C,D). The results of our behavioral 
experiments support the observation that Setd1b mutations in humans are correlated with 
intellectual disability4,124,125. Phenotypically, the Setd1b cKO mice appear to be slightly 
smaller, with a reduced body and brain weight, when compared to the control animals 
(see Fig.2A,B). This has to be taken into consideration when interpreting the behavioral 
results, as the Setd1b cKO mice might be in a reduced physiological state, maybe due to 
reduced food intake, making it more difficult for them to feed, nest, swim or hold on the 
rod. Due to these concerns, we wanted to reduce the area in the mouse brain, in which 
Setd1b is inactivated, to the DG region. For this endeavor, using stereo-tactical injections, 
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we have injected Adeno-Associated-Virus (AAV) bearing Cre-GFP into the hippocampus 
of Setd1b mice. In the fluorescence microscopy, parts of the hippocampus and the DG 
region were indeed GFP positive (see Supp.Fig.5A,B). However, qPCR analysis revealed, 
that Cre and GFP mRNA levels were indeed upregulated, but Setd1b mRNA levels 
remained unchanged (see Supp.Fig.5C,D). Thus, the injections were negative and injected 
mice were not subjected to behavioral experiments. This was a puzzling result for us, but 
it could be explained by the findings that we made with the single cell sequencing 
approach, which showed that Setd1b is only expressed in a subset of neurons. If the 
injected virus did not transfect into these Sedt1b positive cells, the total Setd1b mRNA 
in the qPCR analysis might remain unchanged. Our experimental approaches must 
therefore be designed similar to the Setd1b cKO mouse model, and only target the subset 
of Setd1b expressing neurons, to obtain a similar phenotype. And finally, as our 
pharmacological intervention with the HDAC inhibitor SAHA did not rescue the cognitive 
impairment phenotype in Setd1b cKO mice (see Fig.13), it can also be assumed, that the 
global upregulation of histone acetylation does not rescue the phenotype. It is therefore 
possible, that only the subset of Setd1b expressing neurons should be targeted by the 
drug, and a global upregulation of histone acetylation might actually impede the 
reconstitution of synaptic plasticity. The finding, that only a subset of neurons in the 
mouse hippocampus express Setd1b, is a crucial observation, which would have heavily 
influenced experimental decisions if it was discovered earlier in the project. Taken 
together, Setd1b expressing neurons might function as nucleating factors to promote 
neuronal identity and synaptic plasticity in the mouse forebrain.  
 
6.2. Dramatic deficits in nesting behavior of Setd1b cKO 
 
Nesting is an evolutionarily ancient behavior and is common for many animals, including 
fish, birds, rodents and apes. Nests provide to mammals a secure environment, 
maintaining the body thermoregulation, protection from predators and are crucial for 
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parental behavior180. The inability to build nests is found to be correlated with impaired 
social behavior181. Normally, a piece of cotton introduced to a mouse cage is torn by the 
animal and piled up to form a single structure. The striking observation we made with 
Setd1b cKO mice was that they do not build nests even when supplied with good nesting 
material (see Fig.5A,B). Interestingly, not only did Setd1b cKO mice not build functional 
nests, but the nesting material remained mostly untouched. One could think of impaired 
motoric in Setd1b cKO affecting the nesting process, since it requires physical performance 
to rip a nestlet. Our results of other tests, such as immobility time in tail suspension test, 
speed in the open field, elevated plus maze and Morris water maze are arguing against it, 
since cKO and WT animals did not differ in performance and only motor learning was 
moderately decreased in rotarod test. We also cannot claim that animals failed to build 
nests due to apathetic behavior, since they did not have signs of depression according to 
the tail suspension test. Kmt2a-CaMKIIa-Cre cKO mice also show impairments in 
nesting174, indicating that H3K4 trimethylation in the mouse forebrain seems to play an 
important role in nesting behavior. We have attempted to rescue the phenotype with the 
HDAC inhibitor SAHA111, as HDAC inhibition has been shown to rescue Kmt2d deficiency 
induced learning impairments89. H3K9ac was significantly decreased in Setd1b cKO cells 
(see Supp.Fig.6), however, we did not see a rescue of nesting behavior in SAHA treated 
Setd1b cKO mice. 
 
6.2.1. Neurological disorders and impairment of nesting behavior 
 
Impaired nesting has been reported in multiple mouse models mimicking 
neurodevelopmental, neurodegeneration and neuropsychiatric disorders of genetic origin. 
For instance, the Fragile X Mental Retardation 1 (FMR1) gene in mice, linked to Fragile 
X syndrome in humans and characterized by mental retardation and autism, encoding 
the translational repressor protein FMRP also results in impaired nesting182.  
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Rett syndrome is a neuropsychiatric disorder associated with sensory, cognitive and motor 
deficits and derives from gain of function or loss of function of methyl CpG-binding protein 
2 (Mecp2). Mice with truncated Mecp2 allele show multiple symptomatic phenotypes, 
including compromised nest building, Morris water maze spatial learning difficulties183 and 
mice with 95% knock-out of Mecp2 exhibit impaired nesting, while reactivation of Mecp2 
in the CNS restores the phenotype184. 
 
Autism spectrum disorders (ASD) unite etiologically diverse neurodevelopmental 
conditions with multiple cognitive symptoms, such as compromised verbal and social 
communication, stereotyped behaviors and limited interests245. Many autism mouse models 
have shown the absence of nest-building behavior. Animals with mutated presynaptic cell 
adhesion protein neurexin1a (Nrxn1), phosphatase and tensin homologue (Pten), gamma-
aminobutyric acid type A receptor subunit beta 3 (Gabrb3), tuberous sclerosis-1 (Tsc1) 
exhibit impaired nest building. All of these genes have been reported in the patients with 
autism185. Mutations in synaptic cell adhesion molecules neuroligin-1 (Nlgn1) and 
neuroligin-4 (Nlgn4), the most frequent monogenic cause of autism186, have been 
documented in ASD, and mice with dysfunction of the corresponding protein are unable 
to build nests. Another autism-associated loss of function mutations in the SH3 and 
multiple ankyrin repeat domains 2 gene (Shank2) and SH3 and multiple ankyrin repeat 
domains 3 gene (Shank3)187 also produce poor nest builders. ASD-related contactin 
associated protein-like2 (Cntnap2) knockout mice fail to make nests and the FDA 
approved antagonist of dopamine D2 receptor and serotonin 5-HT2a receptor risperidone 
was able to improve the nesting score188. Among the above-mentioned genes, we have 
observed significantly decreased H3K4me3 at the Nrxn1, Pten, Shank2 and Cntnap2 loci, 
but only Nrxn1 was significantly downregulated in the whole tissue RNA-seq data and 
not in the neuronal RNA-seq (see Supp.Tabl.19). 
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Decline in nesting activity was suggested to mirror negative symptoms of schizophrenia 
and treatment of mice with the NMDA receptor antagonist phencyclidine (PCP, drug 
used to model schizophrenia) caused a significant nest building deficit189. Postnatal loss of 
glutamate ionotropic receptor NMDA subunit 1 (Grin1) from corticolimbic interneurons 
affects nest formation and results in other behaviors associated with schizophrenia, such 
as impaired PPI190. The gene has also been found to be affected among schizophrenia 
patients191,192. As previously mentioned, the Grin1 gene is responsible for striatal motor 
learning and a normal startle response amplitude, both of the behaviors are impaired in 
Setd1b cKO. In our dataset, we have discovered a reduction of Grin1 trimethylation levels, 
but this effect was not observed on the gene expression level. However, the gene expression 
levels of glutamate ionotropic receptor NMDA type subunit associated protein 1 (Grina) 
and glutamate ionotropic receptor NMDA type subunit 3A (Grin3a) are decreased in the 
NeuN+ RNA-seq dataset (see Supp.Tabl.19). Therefore, glutamatergic signaling could be 
compromised among Setd1b cKO animals. 
 
A triple transgenic mouse model of the Alzheimer’s disease, 3xTg-AD, mimicking familial 
AD mutations in PS1/M146V, AßAPPSwe and tauP301L showed age-dependent 
regression of nest building193. Offspring of hAPP and htau mouse strains, possessing the 
amyloid and tau features of AD, were also unable to build functional nests194. The same 
refers to the Tg2576 mouse model, which overexpresses the amyloid-beta precursor APP195 
and the APPswe/PS1 bigenic model of AD196. 
 
Hypothalamus is responsible for parental-related hormone release, such as oxytocin and 
vasopressin, and has been shown to be responsible for nest building behavior in mice197,198. 
We cannot exclude that the absence of nesting behavior among Setd1b cKO animals is 
due to deregulated gene expression within the hypothalamus region since the driving 
promotor of our line, CamKIIa, is still moderately expressed within the hypothalamic 
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region (Allen Brain Atlas). However, lesions of the hippocampus modeled with 
intrahippocampal injections of scarpie (prionic protein) resulted in worse nest building 
scores, whereas cytotoxic lesions of the prefrontal cortex did not result in a similar 
phenotype156. This might indicate a crucial role of the hippocampus in recognition of nest-
like structures181. It was also shown that there are nest responsive CA1 hippocampal cells 
firing during mouse engagement with beds and nests199.  
 
6.2.2. Neurotransmitter metabolism and impairment of nesting behavior 
 
In our dataset, the serotonin receptor signaling pathway appeared among one of the 
most downregulated pathways in the NeuN+ RNA-seq (see Table 16) and we could 








log2FoldChange in NeuN+ 
H3K4me3 ChIP-seq 
(padj<0.05) 
Htr1a 5-Hydroxytryptamine receptor 1a -1,3102 -0.39 
Htr4 5-Hydroxytryptamine receptor 4 -0,3161 -2.17 
Htr2a 5-Hydroxytryptamine receptor 2a -0,6787 -0.71 
Htr1b 5-Hydroxytryptamine receptor 1b -0,5096 -3.6 
Htr5b 5-Hydroxytryptamine receptor 5b -1,0506 -0.46 
Table 16: Genes from the downregulated GO-pathway “Serotonin receptor signaling 
pathway” from neuronal RNA-seq 
 
Knockout of the 5-Hydroxytryptamine receptor 4 (Htr4) has previously been linked to the 
impaired nesting behavior200. The mouse line Ts65Dn, carrying three copies of murine 
chromosome 16, 17 and a partially homologous human chromosome 21, is mimicking Down 
syndrome, fails to build proper nests in a novel environment201. These mice had increased 
levels of Htr2a and serotonin in the frontal cortex, but not in the hippocampus. Htr2a 
blockade with risperidone, an antagonist of the serotonin receptor, caused restoration of 
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context-dependent nest building, while Htr2a activation disrupted it. Htr1a was one of 
the overlapping genes between the Setd1a KO model of schizophrenia176 and our Setd1b 
cKO mice (see Supp.Fig.9A,B), serotonin signaling is therefore impaired in the both 
Setd1a and Setd1b. 
 
Serotonin availability can be influenced not only by receptors, but also by serotonin 
producing enzymes and serotonin transporters. Tryptophan hydroxylase 1 (Tph1) and 
tryptophan hydroxylase 2 (Tph2) are encoding proteins responsible for the first and rate 
limiting step of serotonin biosynthesis; solute carrier family 6 member 4 (Slc6a4), is coding 
for a serotonin transporter. None of them were affected by Setd1b cKO on trimethylation 
or gene expression level. Slc6a4 and Tph2 have been associated with altered serotonin 
levels and polymorphisms in autism patients202–204. Tph2 null mutant female mice exhibit 
decreased maternal care skills and are poor at nest building205. The selective serotonin 
reuptake inhibitor (SSRI) fluoxetine provided to pregnant female mice showed that 
prenatal exposure to SSRI altered maternal nest building among the offspring206 and a 
number of SSRI (clomipramine, citalopram, fluoxetine and venlafaxine) has inhibited 
nestlet shredding in a dose-dependent manner207. 
 
Even though it is widely accepted that nesting is an innate behavior, there are certain 
incidences when it can be disrupted in adult rodents. For instance, it has been shown that 
amphetamine, mescaline (can bind to Htr2a) and lysergic acid diethylamide can affect 
nest building in adult mice208. Setd1b cKO mice also exhibit changes in dopamine 
signaling. It has been reported that dopamine deficient mice lacking tyrosine hydroxylase 
(Th), encoding a tyrosine to dopamine conversion enzyme, have impaired nesting, but 
could be restored by restoration of dopamine production via viral delivery into the caudate 
putamen209. Dopamine receptor D2 (Drd2) mutant mice have decreased goal-oriented 
behavior and lack of motivation210. In our Setd1b cKO animals we discovered 
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downregulation of the dopamine receptor D1 (Drd1), indicating that Setd1b directly 
regulates Drd1 expression via promoter methylation (see Supp.Fig.10).  
 
We suspect the nesting circuit, mediated by oxytocin and vasopressin, to be compromised 
in Setd1b mice. Oxytocin is a posterior pituitary peptide hormone and it is important for 
the induction of labor and breastfeeding in mammals211. It is also facilitating nesting 
behavior212 and even can cause “false-nesting” (nesting behavior without egg laying) in 
turtles after intramuscular injections213.  
 
The three main components of oxytocin action are the oxytocin structural gene Oxt, the 
oxytocin receptor Oxtr and the CD38 antigen, which is responsible for oxytocin secretion. 
Since oxytocin plasma levels are lower in ASD patients214, it is an interesting question to 
ask, whether Setd1b cKO mice exhibit decreased amounts of oxytocin. The Oxtr 
transcript was downregulated in our NeuN+ RNA-seq of Setd1b cKO mice (see 
Supp.Fig.10), an absence of sufficient receptor amounts consequently could have caused 
nesting behavioral impairment. CamKIIa cKO mice lacking Oxtr exhibit impaired social 
memory215, the gene has also been reported to be involved in ASD216. CD38 deficient mice 
also exhibit deficits in social behavior217, and it was strongly downregulated in our NeuN+ 
RNA-seq data of the Setd1b cKO. Downstream oxytocin physiology involves MAPK 
signaling218. Interestingly, the positive regulation of ERK1 and ERK2 cascade was the 
most downregulated pathway from our Setd1b cKO neuronal RNA-seq (see Supp.Table 
18), which might be an indication that oxytocin signaling is indeed disrupted. This goes 
together with mitogen-activated protein kinase 1 (Mapk1, old name Erk2) deficiency 
known to cause ASD-like phenotype in mice including impaired nest formation219. Taken 
together, we present strong evidence for deregulated oxytocin-related aberrant nesting 
behavior among Setd1b cKO mice. 
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Increased levels of vasopressin were shown to inhibit nest building, both on the genetic 
and pharmacological level197. The vasopressin gene (Avp) does not appear as differentially 
expressed in our data. However, the vasopressin 1b receptor (Avpr1b) was significantly 
downregulated in the whole tissue RNA-seq of the CA region. Avpr1b KO in mice results 
in the reduction of social recognition220 and reduced ultrasonic vocalization in pups, 
abnormalities associated with the autistic spectrum disorders. There is no published data 
on nesting behavior upon Avpr1b loss in mice. 
 
In conclusion, the nesting phenotype observed in our case can been seen in different mouse 
models of autism, mental retardations and intellectual disabilities, schizophrenia and the 
Alzheimer’s disease. Nesting can be affected by genetic, biological and environmental 
factors. Aberrant serotonin and dopamine signaling, oxytocin and vasopressin regulation 
might be the underlying causes of the nesting impairment phenotype in Setd1b cKO mice. 
 
6.3. Setd1b exerts distinct functions from other H3K4 methyltransferases in the 
mouse forebrain 
 
H3K4 methylation has been shown to increase during mouse behavioral training76 and has 
also been found to be reduced in AD mouse models221 and post mortem tissues of patient 
brains with cognitive disorders222. Similarly to our findings in Setd1b (see Fig.3), Kmt2a78 
and Kmt2b77 forebrain cKO mice also exhibited impairment in hippocampal memory 
functions in behavioral experiments. Importantly, mice heterozygous for the Setd1b 
homologue Setd1a are not impaired in hippocampal memory formation, but rather exhibit 
working memory defects and schizophrenia-like phenotype176, although a forebrain specific 
cKO could perform differently. Together with our ChIP and RNA sequencing data, we 
provide proof that the four H3K4 methyltransferases exert distinct functions in the mouse 
forebrain. We show differentially decreased H3K4me3 at TSS of distinct genes in Setd1b, 
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Kmt2a and Kmt2b cKO mice (see Fig.10A). Alterations of H3K4me3 levels seem to impact 
H3K9ac levels as well (see Fig.8C), this finding is supported by previous studies, which 
link H3K9ac downstream to H3K4me377,223. One key finding of our screens was that a 
number of genes with decreased H3K4me3 in the Setd1b cKO samples in turn showed 
increased H3K4me1 levels at TSS (see Fig.10B), which was not observed for Kmt2a and 
Kmt2b cKO mouse samples. These genes were further investigated and turned out to 
exhibit a reduced H3K4me3 peak width when compared with the control (see Fig.10H). 
Furthermore, these genes are highly expressed at basal levels (see Fig.10I) and function 
in pathways promoting neuronal identity, synaptic plasticity, learning and memory 
functions (see Fig,10J). The association between reduced H3K4me3 peak width, enhanced 
H3K4me1 and high basal gene expression has been reported previously with the Setd1b 
yeast homologue Set1 . A possible explanation for the increased H3K4me1 levels around 
TSS in Setd1b regulated genes might be the subsequence of H3K4me1 to H3K4me3171. 
Together with our single cell sequencing data, which showed that only a subset of neurons 
expressed Setd1b (see Fig.11E) and that Setd1b specifically and strongly regulates a subset 
of genes in these cells (see Fig.11F), we hypothesize H3K4me1 to be the incompletely 
methylated H3K4me3 transitional state at Setd1b regulated TSS, as Setd1b specifically 
regulates these genes while having little overlap with the other KMTs. Therefore, the 
specific dependency on Setd1b will accumulate H3K4me1 at TSS without further 
methylation processing by other H3K4 methyltransferases, this situation might be 
compensated in the Kmt2a and Kmt2b cKO mice by other KMTs. A possible experiment 
to prove this hypothesis is a Setd1b knockdown or knockout in primary neuronal cells 
with subsequent ChIP analysis of H3K4me1 levels at TSS. This short term Setd1b loss of 
function should expose the H3K4me3 transient state H3K4me1, which could be rescued 
with Setd1b overexpression. Furthermore, it would be interesting, whether a Kmt2a and 
Kmt2b double cKO would also expose genes with increased H3K4me1 levels at TSS. 
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The discovery that Setd1b is only active in a subset of neurons is intriguing. For one, it 
suggests that NeuN+ sorted cells do not resemble a homogenous population of neurons 
(see Fig.7), there are subgroups of neuronal cells, which can be, in our case, distinguished 
by the activity of different H3K4 methyltransferases in the single cell sequencing data (see 
Fig.11F). It would therefore be interesting, to further characterize these subgroups by in 
depth analysis of the differences in gene expression. Furthermore, these different 
populations might play specific roles in the neuronal network and even have specific 
positioning in the architecture of the brain. Evidence for such heterogeneity in the 
neuronal population has been provided by other research groups utilizing the single cell 
sequencing technology. In one study, it was shown in single cell data that cells expressing 
Pvalb (Parvalbumin) were actually a distinct cell population among interneurons and that 
Vip (Vasoactive intestinal peptide) expression defines a subset of Calb2 (Calbindin 2) 
expressing cells225. The authors were able to further subdivide the Pvalb and Vip 
populations by differential gene expression in the single cell datasets. Furthermore, they 
identified a subpopulation of NeuN positive neurons which express Cplx3 (Complexin 3). 
The hitherto known group of neuronal cells is therefore highly heterogenous and we are 
just beginning to understand their diversity. Technologies such as single cell sequencing 
or sorted cell sequencing will rapidly push this frontier of understanding and categorizing 
these distinct neuronal cell populations. Large scale screens for such distinct neuronal 
subtypes of the brain have been conducted and need to be thoroughly evaluated226, the 
same is true for neuronal disease datasets, such as from AD patients227. With our work, 
we provide evidence that in the group of NeuN+ cells Kmt2a, Kmt2b and Setd1b 
expression is differential (see Fig.11E,F). As epigenetic regulators such as H3K4 
methyltransferases play a key role in regulating the overall cell fate and thus gene 
expression, their differential expression might play a key role in regulating the overall 
cellular organization and functions of the brain.  
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Another interesting question raised by the observation of the complex diversity of neurons 
is their positioning within the architecture of the neuronal network. Setd1b is expressed 
in a minority of NeuN+ cells, which is distinct to Kmt2a and Kmt2b (see Fig.11E,F). It 
would therefore not be plausible, if Setd1b cells would cluster in a distinct location in the 
hippocampus, it would rather have a dispersed distribution to promote neuronal fate and 
synaptic plasticity all over the brain structure. Therefore, it would be really interesting to 
investigate the positioning of different neurons in their smallest functional unit. Molecular 
mapping of neuronal distribution in the mouse brain has been conducted and yielded a 
really impressive database228, but due to the sheer number of neurons in the mammalian 
brain, the data is insufficient to create a map in single neuron interaction resolution. It 
would therefore be feasible to investigate neuron positioning in the brain network in 
simpler organisms, such as the zebrafish embryo. The zebrafish Danio rerio is an 
established model organism in neuroscience229, besides cheap housing and short generation 
times, it can be engineered to be transgenic and most importantly, it has a transparent 
embryo230. For the investigation of Setd1b in the zebrafish in vivo, one could genetically 
engineer a strain in which GFP is behind the Setd1b promoter. Imaging of neurogenesis 
and the adult brain could reveal the specific positioning of Setd1b cells within the fish 
brain. Setd1b is conserved from zebrafish to human and has already been shown in in situ 
hybridization experiments in the fish, in which a strong staining of the brain could be 
observed4. However, these results are unable to resolve the fish brain in a three-
dimensional neuronal network with single cell interaction resolution. Therefore, a 
Setd1b::GFP transgenic fish might reveal the spatial positioning of Setd1b expressing cells 
within the neuronal network architecture. Introduction of further promoter driven 
fluorescent proteins could visualize the smallest interaction unit of Setd1b expressing cells 
with other neurons, for instance with Kmt2a or Kmt2b expressing cells. Such data could 
help understand the general function of Setd1b expressing neurons and H3K4 
methyltransferase differential distribution in the vertebrate brain. 
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6.4. Spatial memory deficits in KMT cKOs and the Oxr1 gene   
 
We have observed a spatial memory impairment with deficits in learning the hidden 
platform location and compromised memory retention on the probe test day in the MWM 
experiment with Setd1b cKO animals (see Fig.3). Spatial navigation is strongly dependent 
on hippocampal function231, which appears to be compromised in Setd1b cKO according 
to our behavioral and sequencing data. Multiple origins of impaired spatial learning have 
been reported, including ASD232,233, AD234,235 and schizophrenia236.  
 
Kmt2a, Kmt2b and Setd1b cKO animals all exhibit impairment of spatial learning in the 
MWM experiment, and the analysis of sequencing data reveals only one common 
downregulated gene, Oxr1 (see Fig.12). Oxr1 is known to protect against oxidative stress-
induced damage, it was initially discovered in E.coli as a DNA oxidative stress protector237. 
It has also been shown to be an essential protector against oxidative stress in the 
mammalian central nervous system (CNS) and has been linked to cerebellar 
neurodegeneration238. Neuronal Oxr1 overexpression leads to motor improvement and 
increases lifespan in the amyotrophic lateral sclerosis (ALS) SODG93A mouse model239. 
Lentiviral overexpression of Oxr1 was able to ameliorate a Parkinson’s disease phenotype 
in the corresponding mouse model, including trembling and rigidity of limbs. Depletion of 
miR-137, a negative regulator of Oxr1, reduced oxidative stress from neurons240. A very 
recent study identified the biallelic loss of Oxr1 in individual with intellectual disability, 
cerebellar atrophy, developmental delay and seizures241. Interestingly, Oxr1 transcripts are 
colocalized with CamKIIa transcripts and not with Glutamic Acid Decarboxylase (GAD), 
indicating expression only in excitatory neurons242. Interestingly, ROS are required for 
learning and memory, participating in their signal transduction cascades243 and at the 
same time has been shown to be involved in pathological conditions, such as the Parkinson 
disease, AD, depression, schizophrenia and ASD244. Taken together, downregulation of 
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Oxr1 might have compromised the attenuated spatial learning and memory retrieval in 
MWM of Kmt2a, Kmt2b and Setd1b cKO mice through an imbalance of oxidation levels.     
 
6.5. Setd1b regulates the claustrophobia-mediating gene Gpm6a 
First, we had difficulties interpreting the data of fear conditioning test, since such behavior 
has been never observed before in our laboratory. While trying to find any explanation 
for such behavior we came across the paper dedicated to the study of claustrophobia, the 
fear of being trapped in the closed spaces. Researchers for the first time discovered that 
mice lacking the neuronal tetraspan membrane glycoprotein (Gpm6a) gene exhibit 
“claustrophobia-like” phenotype, including avoidance of the closed arms in EPM245. We 
notice the same trend among our cKO animals (see Fig.4A,B). Gpm6a were selecting wide 
areas in the wide/narrow box and avoiding dark spaces in the light/dark box. This is not 
very natural for rodents, who usually prefer to hide from predators in the small dark 
places. Researches also confirmed mouse data by analyzing human samples and finding 
rare sequence variants in the Gpm6a. But the most striking, however, was their 
observation that Gpm6a mutants had higher baseline freezing in the fear conditioning 
chamber, same as Setd1b cKO. Gpm6a mutants had increased basal levels of 
corticosterone in urine, while in our knock-out animals we did not observe elevated levels 
of the stress hormone in plasma (see Supp.Fig.4).  
 
Trimethylation of H3K4 as well as H3K9 acetylation of Gpm6a in the hippocampi of 
Setd1b cKO is significantly decreased and it is also strongly deregulated on mRNA level 
in both, whole tissue and neuronal RNA-seq from our data (see Supp.Fig.11). This 
indicates that Setd1b can be direct regulator of Gpm6a by mediating promoter 
methylation and, therefore, affecting the expression levels. We cannot be sure, whether 
the Gpm6a function is hippocampus-specific, but even for the case of other brain regions 
we can assume that Setd1b regulates the expression of Gpm6a in those areas. 
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6.6. SAHA is not efficient to compensate methylation losses 
Even though the treatment of neurodevelopmental disorders is majorly performed via 
behavioral therapy and symptoms management, agents that promote chromatin opening 
can have therapeutic potential and histone deacetylase inhibitors are one of them. Oral 
administration of HDACi AR-42 was able to rescue Morris water maze performance and 
H3K4me3 levels in Kabuki syndrome mouse model with the absence of Kmt2d allele89. 
Water administration of SAHA to Setd1b cKO mice did not reverse nest building behavior 
and did not improve memory retrieval during probe tests of MWM, however we observed 
a trend on the first probe test as well as in the speed of learning for before the first probe 
test among SAHA treated cKO animals. It might be that SAHA was indeed improving 
learning and memory for Setd1b cKO mice but the total number of animals was not 
sufficient to make proper statistical conclusions. It is further possible that the oral SAHA 
delivery was not successful. Also, the pharmacological rescue of the Setd1b cognitive 
impairment phenotype might not be easily achieved, as the specific targeting of Setd1b 
expressing neurons is difficult to obtain with systematically applied HDAC inhibitors. 
 
6.7. IGFBP7 overexpression in the murine liver does not impact learning and 
memory formation in transgenic animals 
 
Previous work in our lab has identified elevated levels of IGFBP7 in the blood serum of 
AD patients (see Fig.14B), which gave rise to the hypothesis, that artificial enhancement 
of IGFBP7 in the mouse could lead to the impairment of cognitive functions in behavioral 
experiments. For this endeavor, we have designed a transgenic mouse, that overexpresses 
the IGFBP7 protein in the liver, which has been verified by qPCR analysis (see Fig.14D). 
However, these transgenic animals did not show cognitive impairments or memory deficits 
in the behavioral studies when compared to wildtype animals, prompting the conclusion, 
that overexpression of IGFBP7 is not sufficient to induce a cognitive impairment 
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phenotype in mice. We are currently validating in cooperation with DZNE Bonn, whether 
our transgenic animals do indeed possess elevated plasma levels of IGFBP7. The result 
will determine, whether the transgenic model is to be questioned or whether IGFBP7 







Supplementary Figure 1. (A) Behavioral analysis of mice expressing CamKII-driven Cre recombinase. Body 
weight did not differ between cre+ and cre- mice. (B) The distance traveled in the open filed test and (C) 
the time spent in the center of OF was comparable among the groups. (D) In the Morris water maze mice 
had the same speed on the first trial of the first day. (E) Escape latency was similar between cre+ and cre- 
mice and both grouped learned the platform location. (F) % of time in the target quadrant and (G) the 
number of platform crossings did not differ among two groups at the probe test conducted after 10 days of 
training. (H) In contextual fear conditioning test cre+ mice did not exhibit freezing before foot-shock and 
had comparable time freezing after electric shock exposure (two-way ANOVA, p-value=0.1145). (I) Cre+ 
mice spend the same amount of time near new object in novel object recognition test. 8 mice of each group 




Supplementary Figure 2. Attempt to initiate AAV-mediated DG-specific Setd1b loss did not succeed. (A) 
Analyzing expression of Setd1b in viral-injected DG measured with qPCR we did not observe the loss of 
Setd1b in AAV-treated Setd1bfl/fl samples comparing to cKO samples. Cre-recombinase expression upon 
virus delivery was sufficient. For convenience, data on Setd1b and cre-recombinase expression in cKO and 
WT mice used for this study is also presented. (+/+ AAV, n=10; fl/fl AAV, n=10; WT, n=8; cKO, n=8; 
Student’s t-test, error bars indicate SEM). (B) Immunofluorescent staining of GFP signal within AAV-cre 




Supplementary Figure 3. Spatial memory impairment in Morris water maze test is not gender-related. 




Supplementary Figure 4. Stress hormone corticosterone is not elevated in the blood of Setd1b cKO mice. 
5 mice of each group were tested, Student’s t-test, error bars indicate SEM.  
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Supplementary Figure 5. The most downregulated genes from whole-tissue DG (left) and CA region 




Supplementary Figure 6. Total number of differentially methylated and acetylated regions in 




Supplementary Figure 7. Genome-wide distribution statistics of H3K4me3 in Kmt2a, Kmt2b and 







Supplementary figure 8. Heat map showing functional pathways for the 3 categories of genes affected by 





Supplementary figure 9. Genes common for downregulated and upregulated genes for Setd1b cKO (CA-
region whole tissue RNA-seq) and Setd1a loss-of-function allele KO (PFC whole tissue RNA seq from 
published study176. (A) Venn diagram for overlapping downregulated genes. (B) List of overlapping up- 
and downregulated genes. Fold change>1.2, padj<0.1. 
 
 
Supplementary Figure 10. IGB profiles for target genes causing nesting defect in Setd1b cKO animals: 
Htr1a, Drd1, Oxtr. 
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Supplementary Figure 11. IGB profile for Gpm6a gene causing claustrophobia-like behavior in Setd1b 
cKO mice. H3K4me3 peak is strongly decreased in Gpm6a gene (Log2FoldChange=-1.93, padj<0.05) as 
well as expression levels in NeuN+ RNA-seq (Log2FoldChange=-0.5927, padj<0.1), indicating that 
Setd1b is a direct regulator of Gpm6a gene expression.  
 
 
Name Gene name Sequence 





Npy2r_tr1_F  Neuropeptide Y receptor Y2 taagctgaggaaccacgtca 
Npy2r_tr1_R gtgccttcgctgatggtaat 




Npy2r_tr2_F Neuropeptide Y receptor Y2 taagctgaggaaccacgtca 
Npy2r_tr2_R gtgccttcgctgatggtaat 
Dcn_F Decorin cttctttccacacctgcaaac 
Dcn_R ccctcaaagctgcgatgta 




Lgi_F Leicine-rich glioma inactivated ctgcccaggataagtctggt 
Lgi_R tgcttctttggagactgtgtg 









Sstr4_F Somatostatin receptor 4 cttctgcctcaccgtgct 
Sstr4_R cacactcccaggttgattagc 




Name Gene name sequence 
Trpa1_F Transient receptor potential 




Sult5a_F Sulfotransferase 5 agcctgtcctcctactgtgc 
Sult5a_R tagaccaggggcgtagca 
Npr1_F 
Natriuretic peptide receptor 6 
aaggagctggtctcagagttgt 
Npr1_R ctccgaaggtgcctctcc 
Neurod6_F Neuronal differentiation 6 aacaactattcctcttcaagcatttt 
Neurod6_R ataacctcccccaaataccg 
Prdm5_F PR/SET domain 5 caccttcagtgcttaggagtca 
Prdm5_R gccacaatatgggcagactt 
Vill_F Villin like cctggggccttgagtacc 
Vill_R ttgcttgaccacaaagatgg 




Gene name Encoded protein log2FoldChange adjusted p-value 
Pdgfb 
Platelet Derived Growth 
Factor Subunit B -0,47619 0,00277 
Ctgf 
Connective tissue growth 
factor -0,61095 0,00360 
Vegfa 
Vascular endothelial 
growth factor -0,40517 0,00017 
Hras 
Harvey rat sarcoma virus 
oncogene -0,30559 0,02860 
Nrp1 Neuropilin 1 -0,58547 0,00000 
Pdgfa 
Platelet derived growth 
factor alpha -0,34224 0,00945 
Fbxw7 
F-box and WD-40 domain 
protein 7 -0,37384 0,00187 
Mt3 Metallothionein 3 -0,29980 0,01809 
Htr2a 
5-hydroxytryptamine 
receptor 2A -0,67873 0,00000 
Abca7 
ATP-binding cassette, 
sub-family A, member 7 -0,32750 0,03331 
Rara 
Retinoic acid receptor 




containing 1 -0,53256 0,01173 
Sema7a Semaphorin 7A -0,28726 0,07704 
Npnt Nephronectin -0,42466 0,00616 
Ackr3 
Atypical chemokine 
receptor 3 -0,69140 0,00000 
Arrb2 Arrestin beta 2 -0,33221 0,02610 
Kdr 
Kinase insert domain 
receptor -0,43525 0,01888 
Supplemental Table 18. Genes from the most downregulated GO-pathway “Positive 

















neurexin1a -2.3411 (whole 
tissue) -2.21 
Pten 
phostphatase and tensin 
homologue Not significant -0.95 
Shank2 
SH3 and multiple ankyrin 
repeat domains 2  Not significant -0.92 
Cntnap2 
contactin associated protein-
like2 Not significant -3.13 
Grina 
glutamate ionotropic receptor 
NMDA type subunit 
associated protein 1 -0.2775 (NeuN+) Not significant 
Grin3a 
glutamate ionotropic receptor 
NMDA type subunit 3A -0.308 (NeuN+) Not significant 
Grin2a 
glutamate ionotropic receptor 
NMDA type subunit 2A Not significant -0.99 
Grin1 
glutamate ionotropic receptor 
NMDA type subunit 1 Not significant -0.84 
Grin2d 
glutamate ionotropic receptor 
NMDA type subunit 2D Not significant -0.73 
Drd1 dopamine receptor D1 -0.4323 (NeuN+) -2.69 
Oxtr oxytocin receptor -0.4938 (NeuN+) Not significant 
Cd38 CD38 antigen -1.2815 (NeuN+) Not significant 
Avpr1b 
vasopressin 1b receptor -0.6114 (whole 
tissue) Not significant 
Supplemental Table 19. Target genes identified in this study as the causes of impaired 
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